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Abstract: Secondary nonalcoholic fatty liver disease (NAFLD) defines those complex
pathophysiological and clinical consequences that ensue when the liver becomes an ectopic site of lipid
storage owing to reasons other than its mutual association with the metabolic syndrome. Disorders
affecting gonadal hormones, thyroid hormones, or growth hormones (GH) may cause secondary
forms of NAFLD, which exhibit specific pathophysiologic features and, in theory, the possibility to
receive an effective treatment. Here, we critically discuss epidemiological and pathophysiological
features, as well as principles of diagnosis and management of some common endocrine diseases,
such as polycystic ovary syndrome (PCOS), hypothyroidism, hypogonadism, and GH deficiency.
Collectively, these forms of NAFLD secondary to specific endocrine derangements may be envisaged
as a naturally occurring disease model of NAFLD in humans. Improved understanding of such
endocrine secondary forms of NAFLD promises to disclose novel clinical associations and innovative
therapeutic approaches, which may potentially be applied also to selected cases of primary NAFLD.
Keywords: GH deficiency; hypogonadism; hypothyroidism; PCOS
1. Introduction
When the liver becomes an ectopic deposit of fatty substrates, which is not one of the
physiologic functions of this organ, a cascade of pathophysiological and clinical consequences
will ensue. Collectively, these complex metabolic, hepatic, and extra-hepatic consequences are
referred to as nonalcoholic fatty liver disease (NAFLD) [1,2]. While the global burden of NAFLD
has been elucidated [3–5], the pharmacological treatment of NAFLD remains investigational [6,7].
This therapeutic uncertainty partly reflects our incomplete understanding of the ultimate driving
forces which promote the development and the progression of NAFLD.
The metabolic syndrome defines a set of cardio-metabolic risk factors, primarily comprising
increased visceral adiposity, which amplifies insulin resistance, and predisposes to impaired glucose
tolerance or type 2 diabetes, atherogenic dyslipidemia, and arterial hypertension. These metabolic
abnormalities tend to cluster in a given patient, so that the presence of each of them strongly predicts
the development of other abnormalities over time [8]. Moreover, it is widely appreciated that disorders
causing deranged serum concentrations of sex hormones, thyroid hormones, and growth hormones
(GH) may also predispose to the development of metabolic syndrome [9–13]. This further substantiates
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the assertion that visceral adiposity and metabolic syndrome are closely linked with, and in control of,
multiple hormonal driving forces.
Primary NAFLD may precede, coexist or follow the occurrence of the metabolic syndrome and
its individual features [14]. However, NAFLD may also be secondary to myriads of other causes,
such as chronic use of steatogenic drugs, viral infections, parenteral nutrition, hereditary conditions,
and surgery [15]. Among these causes of secondary NAFLD, some endocrine diseases [e.g., polycystic
ovary syndrome (PCOS), primary hypothyroidism, hypogonadism, and GH deficiency (GHD)]
also rank among the first and best characterized risk factors for the development and progression
of NAFLD [16,17]. For example, hypothyroidism-induced NAFLD recently raised considerable
scientific interest as a distinct disease entity, owing to its strong epidemiological basis and unique
pathophysiology; it also serves as a disease model which may help in identifying innovative therapeutic
avenues virtually amenable to be extrapolated to manage selected cases of primary NAFLD [18,19].
On these grounds, the present review article briefly discusses epidemiological features,
pathophysiological mechanisms, and principles of diagnosis and management of NAFLD in patients
with PCOS, primary hypothyroidism, hypogonadism, or GHD. It should be noted that NAFLD is an
increasingly prevalent and burdensome liver disease, which is probably overlooked by endocrinologists.
Conversely, hepatologists may tend to dismiss underlying endocrine derangements in individuals
exhibiting seemingly primary NAFLD. Therefore, our specific aims are to sensitize practicing physicians,
clinical endocrinologists, and hepatologists to promptly recognize those forms of NAFLD, which may
occur secondary to some common endocrine diseases. In addition, we also aim at prompting researchers
to identify these secondary NAFLD forms as a naturally occurring disease model, characterization
of which may promote a better understanding of pathophysiological mechanisms and management
strategies of all forms of NAFLD, notably including selected cases with primary NAFLD.
2. Polycystic Ovary Syndrome
2.1. Epidemiology and Diagnosis of PCOS
PCOS is the most common form of anovulatory infertility, which affects as many as up to nearly
10% of women of reproductive age in Europe and worldwide, and may also lead to additional health
problems in middle and late adulthood. Indeed, women with PCOS have an increased long-term risk of
developing type 2 diabetes, hypertension, and coagulation disorders, as well as increased cardiovascular
morbidity and mortality [20–22]. In 1935, Stein and Leventhal, two American gynecologists, were first
in describing PCOS by reporting a series of patients exhibiting the syndromic tetrad of ovarian cysts,
chronic anovulation, obesity, and hirsutism [23].
Based on the 2003 Rotterdam diagnostic criteria [24], PCOS is currently diagnosed by the presence
of at least two out of the following three features: clinical and/or biochemical hyperandrogenism,
chronic oligo-anovulation, and polycystic ovarian morphology, after exclusion of other endocrine
disorders, such as hyperprolactinemia, thyroid dysfunction, late-onset congenital adrenal hyperplasia,
or androgen-secreting tumors. It should be pointed out that obesity, which was a component of the
early descriptions of the syndrome, is no longer considered a diagnostic feature of PCOS [24,25].
However, affecting up to ~40% of these patients, obesity is indeed a common finding in PCOS.
The Rotterdam diagnostic criteria introduced at least three different PCOS phenotypes, subsequently
named “classic” (i.e., presence of hyperandrogenism and chronic oligo-anovulation, with or without
polycystic ovarian morphology), “ovulatory” (i.e., presence of hyperandrogenism and polycystic ovarian
morphology), and “normo-androgenic” (i.e., presence of chronic oligo-anovulation and polycystic ovarian
morphology) [24]. As one of the results of this high clinical heterogeneity, women with different
phenotypes of PCOS may also differ in terms of co-existent metabolic disorders. In particular, the risk
of insulin resistance and metabolic syndrome is greatest in women with PCOS exhibiting the “classic”
phenotype, intermediate in those with the “ovulatory” phenotype, and lowest in those with the
“normo-androgenic” phenotype [25,26]. Therefore, physicians must be aware that pharmacological
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approaches to these patients should be personalized by taking into account the specific characteristics
of each individual patient with PCOS. Whether or not these individual differences in both insulin
resistance/metabolic syndrome and androgen excess may also affect the risk of either having NAFLD at
baseline or developing incident NAFLD over time is not entirely clear, although the currently available
evidence suggests that this may indeed be the case.
2.2. Epidemiological Evidence Linking PCOS to NAFLD
An ever-increasing number of cross-sectional and case-control studies strongly suggest that
the prevalence of NAFLD (in most cases diagnosed with ultrasonography) is remarkably increased
in young women with PCOS, regardless of overweight/obesity and other features of the metabolic
syndrome (such as extensively reviewed in Reference [27]). In these studies, the prevalence of NAFLD
in women with PCOS ranges from approximately 35% to 70% compared to approximately 20% to 30% in
age- and body mass index (BMI)-matched control women [27]. Notably, some small case-control studies
performed at tertiary gastroenterology centers also documented that PCOS is highly common among
young women with biopsy-proven NAFLD [28–30]. Indeed, among these patients, the prevalence of
PCOS ranged from approximately 50% to 70%, and these women were also more likely to have the
most severe histological forms of NAFLD (i.e., nonalcoholic steatohepatitis (NASH), advanced fibrosis,
or cirrhosis) [28–30]. With regard to the association between PCOS and the histological severity of
NAFLD, Setji et al. [28] were first in demonstrating the association of biopsy-proven fibrosing NASH
with PCOS in their retrospective chart review study of 200 United States patients with PCOS.
An updated and comprehensive meta-analysis of 17 observational studies, involving a total of
2734 women with PCOS and 2561 healthy women of similar age and BMI, recently confirmed that
young women with PCOS had an almost two-fold higher risk of prevalent NAFLD than control women
(fixed-effects odds ratio (OR) 2.25, 95% confidence intervals (CI) 1.95–2.60; I2 = 57%) [31]. Moreover,
women with PCOS and hyperandrogenism (i.e., the “classic” phenotype) had a significantly higher
risk of prevalent NAFLD, even after adjustment for BMI and other potential confounding factors.
Conversely, normo-androgenic women with PCOS did not seem to have a higher prevalence of NAFLD
when compared to control women [31]. As reported previously, it is reasonable to believe that this
differential impact of the PCOS phenotypes on the risk of developing NAFLD is largely due to the fact
that the risk of insulin resistance and metabolic syndrome is greatest among PCOS women with the
“classic” phenotype, intermediate among those with the “ovulatory” phenotype, and lowest among
those with the “normo-androgenic” phenotype.
Notably, the 13 studies included in the aforementioned meta-analysis, which performed
multivariable logistic regression analyses adjusting for age, BMI, serum triglycerides, and insulin
resistance, confirmed that increased serum androgen levels (i.e., total testosterone and free androgen
index) were independently associated with NAFLD in women with PCOS [31]. Overall, PCOS women
with NAFLD also had significantly higher total testosterone levels (mean difference: 0.40 nmol/L, 95% CI
0.29–0.50 nmol/L) and, especially, higher free androgen index (mean difference: 4.46, 95% CI 3.53–5.39)
than their counterparts without NAFLD [31]. In line with these findings, in a small case-control
study involving young women with PCOS (n = 29) and healthy control women (n = 22) who were
matched for age, BMI, and waist circumference, Jones et al. [32] found that women with PCOS and
hyperandrogenism had markedly higher intra-hepatic fat content (detected by magnetic resonance
spectroscopy (MRS)) than normo-androgenic PCOS women and healthy controls (mean hepatic fat
content: 12.9% vs. 0.6% vs. 1.9%, respectively). These inter-group differences in intra-hepatic fat
content remained statistically significant even after adjustment for BMI, visceral adipose tissue, and
insulin resistance [32]. In a large case-control study, involving 275 non-obese women with PCOS
and 892 non-obese controls, Kim et al. found that women with PCOS had a higher prevalence of
ultrasound-diagnosed NAFLD than those without NAFLD (5.5% vs. 2.8%), and that, in women with
PCOS, the presence of hyperandrogenemia (i.e., higher free testosterone or free androgen index) was
associated with NAFLD, independent of age, BMI, insulin resistance, or glycemic control [33].
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Recently, Kumarendran et al. [34], utilizing a large United Kingdom (UK) primary care database,
performed a population-based retrospective cohort study which included more than 63,000 women
with PCOS and ~121,000 age-, BMI-, and location-matched control women registered between 2000 and
2016. Of interest, these authors were able to show that women with PCOS had an increased incidence
of NAFLD (hazard ratio 2.23, 95% CI 1.86–2.66), even after adjustment for age, BMI, and dysglycemia.
Further to increased BMI and dysglycemia, these authors also identified hyperandrogenism as
an additional risk factor potentially contributing to the development of NAFLD in women with
PCOS [34]. Other studies reported higher free androgen index and lower plasma sex-hormone-binding
globulin (SHBG) levels in PCOS women with NAFLD than in those without NAFLD [35]. However,
other investigators did not find any significant difference in free androgen index or SHBG levels
between PCOS women with and without NAFLD [36,37]. Future studies in larger cohorts of carefully
characterized PCOS women are needed to better elucidate this issue.
2.3. Putative Pathophysiological Mechanisms Linking PCOS with NAFLD
A detailed discussion of the putative underlying biological mechanisms through which PCOS may
promote the development and progression of NAFLD is beyond the scope of this review article and
was more extensively addressed by our group elsewhere [27]. Briefly, there is now an accumulating
body of clinical and experimental evidence suggesting that PCOS and NAFLD share common
pathogenic mechanisms and are part of a more complex and intriguing network of genetic, clinical,
and pathophysiological features (i.e., metabolic, endocrine, and inflammatory abnormalities) [27].
As shown in Figure 1, it is plausible to assume that the pathophysiological mechanisms underpinning
the increased risk of NAFLD in PCOS are multi-factorial, involve both genetic and acquired factors, and
are likely to represent a complex interplay between abdominal adiposity/overweight/obesity, systemic
insulin resistance, chronic inflammation, and hyperandrogenism [27]. Some of these biological actors,
such as abdominal adiposity/overweight/obesity and insulin resistance are acknowledged to be major
players in the general pathophysiology of NAFLD [27,38]. Experimental studies also supported a key
role of insulin in the regulation of ovarian androgen biosynthesis in PCOS. In fact, multiple studies
showed that insulin stimulates androgenesis by increasing ovarian androgen production and decreasing
hepatic SHBG synthesis. The cellular mechanisms via which insulin regulates androgenesis are not
well understood, but potential pathways were proposed [39]. Experimentally, it was demonstrated
that insulin acts through its own receptor in ovarian theca cells. Specific blockade of phosphoinositide
3-kinase (PI3K) in normal human theca cells markedly inhibits the combined insulin and luteinizing
hormone (LH) stimulation of P450c17 activity [40]. It was also demonstrated that insulin stimulates
P450c17 activity through some players of the mitogen-activated protein kinase (MAPK) pathway, such
as MAP kinase-activated protein kinase-3 (MKK3/p38) and MAP kinase-activated protein kinase-4/c-Jun
N-terminal kinase (MKK4/JNK) [41]. On the other hand, specific inhibition of mitogen-activated
protein kinase/extracellular signal-regulated kinase (MEK/ERK), a component of the MAPK insulin
pathway, may increase P450c17 activity. Since insulin stimulates MEK/ERK activity, such a defect
would not contribute to insulin-stimulated androgen production, but it could promote androgenesis or
its responsiveness to stimulation with insulin (via PI3K, MKK3/p38, and MKK4/JNK pathways) and
LH/adrenocorticotropic hormone (ACTH) [39–42].
Several studies showed that androgens may induce adipose tissue dysfunction, with
adverse effects on lipid metabolism, insulin sensitivity, and adipose tissue expansion [43].
Therefore, androgen-mediated adipose lipotoxicity could represent an important mechanism leading
to liver injury in hyperandrogenic PCOS women. Furthermore, in vitro studies also support a direct
adverse effect of androgens on hepatic lipid metabolism in women, with testosterone increasing
lipogenic gene expression and de novo lipogenesis in human hepatocytes from female, but not male,
donors [43]. As discussed below in another section of the article, this sexually dimorphic role of
androgens in human metabolic disease is an emerging topic, with female androgen excess and male
androgen deficiency sharing an overlapping adverse metabolic phenotype, including abdominal
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overweight/obesity, dysglycemia, insulin resistance, and NAFLD [43]. However, further studies
are needed to better elucidate how hyperandrogenism may directly promote the development and
progression of NAFLD in PCOS, and to establish whether treatment with anti-androgenic drugs may
reduce the risk of NAFLD in both lean and obese women with PCOS.
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In the last few years, several abnormalities of ovarian angiogenesis with dysregulation of multiple
angiogenic factors (including vascular endothelial growth fact r, angiopoietins, platelet-derived
growth factor, transforming growth factor-β, and basic fibroblast growth factor) were also described
in women with PCOS [43]. Thus, it was sug ested t at this angiogenic factor dysregulation may
play a role in PCOS pathophysiology, and might also contribute to ovulatory dysfunctio , subfertility,
and ovarian h perstimulatio syndrome, which are commonly observed in PCOS women. Based on
this fascinating topic, future experimental studies will be need d to explore the potential role of
PCOS-related angiogenic factor dysregulation in the development of NAFLD.
2.4. Screening and Therapeutic Approaches to NAFLD in PCOS
Given the growing prevalence of NAFLD in young women with PCOS, who are also at risk of
developing the most advanced histological forms of NAFLD over time, we firmly believe that the
population of young women with PCOS should definitely be considered for systematic screening for
NAFLD, especially whenever obesity and clinical/biochemical hyperandrogenism are also present.
The optimal method to routinely screen for NAFLD patients with PCOS is currently unclear. However,
given the poor sensitivity of serum liver enzyme levels in detecting NAFLD [38], we suggest that,
in patients with PCOS, liver ultrasonography and transient elastography (Fibroscan) combined with
the use of non-invasive fibrosis markers (e.g., either NAFLD fibrosis score or Fibrosis-4 score) should
be used as first-line options for identifying both those individuals with NAFLD and those with
suspected NASH to submit to liver biopsy [38]. Moreover, all patients with PCOS should undergo
regular follow-up examinations not only for liver-related complications but also for cardio-metabolic
diseases [20,21].
Currently, although more research is needed to determine the best approach to management of
NAFLD in women with PCOS, we propose that a more accurate, patient-centered, multidisciplinary
approach to the management and treatment of NAFLD should be considered for young women with
PCOS. A first-line therapeutic approach for NAFLD in women with PCOS should focus on lifestyle
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changes based on hypocaloric diet and increased physical activity [20,25]. A second-line therapeutic
approach should consider lifestyle changes plus drug treatment. Metformin remains the drug of choice
in PCOS [20,25]. Preliminary evidence also suggests some benefit of pioglitazone in the treatment of
women with PCOS [20,44], as well as the use of either liraglutide or other glucagon-like peptide-1
receptor agonists for decreasing intra-hepatic fat content and visceral adipose tissue among women
with PCOS who exhibit overweight/obesity [45,46]. However, to date, there is insufficient evidence
to either support or refute the use of these newer drugs in women with PCOS and NAFLD. A better
understanding of both the complex endocrine regulations of NAFLD and the interconnections linking
PCOS with NAFLD will, in our expectations, also result in future advances in the pharmacological
treatment of this increasingly prevalent and burdensome liver disease.
3. Hypothyroidism
3.1. Diagnosis of Primary Hypothyroidism and Epidemiological Evidence Linking Hypothyroidism
with NAFLD
Hypothyroidism is a common endocrine disease characterized by thyroid hormone deficiency [47].
Classically, primary overt hypothyroidism is defined as serum thyroid-stimulating hormone (TSH)
concentrations above the reference range and free thyroxine (FT4) concentrations below the reference
range [47]. Subclinical hypothyroidism is, instead, defined by serum TSH concentrations above the
reference range and FT4 concentrations within the normal range [47].
The rationale for investigating the association between hypothyroidism and NAFLD is based on
two lines of evidence: firstly, the physiologic capacity of thyroid hormones to contrast the development
of some features of the metabolic syndrome and, secondly, their direct effects on the liver [48–52].
However, the identification of NAFLD in a given patient with hypothyroidism does not necessarily
imply that hypothyroidism is the cause of NAFLD in that specific patient [52]. On these grounds, it can
be argued that not all observational studies and meta-analyses published so far clearly demonstrated a
causal association between primary (subclinical and overt) hypothyroidism and risk of developing
NAFLD, independent of coexisting cardio-metabolic risk factors (Table 1 [53–80]). For instance, in a
large population-based cohort study, involving approximately 9500 Dutch euthyroid individuals
from the Rotterdam Study, Bano et al. showed that both subclinical and overt hypothyroidism were
significantly associated with an increased incidence of NAFLD, as detected with ultrasonography, even
after adjustment for age, sex, BMI, alcohol intake, smoking, lipid profile, hypertension, and diabetes [70].
Similar findings were also reported by Xu et al. in a small prospective case-control study of 327 Chinese
patients with subclinical hypothyroidism and 327 age-, sex-, and BMI-matched euthyroid controls [59].
Interestingly, Bril et al. found that, when serum TSH levels were normal, decreasing FT4 levels were
significantly associated with increasing intra-hepatic fat content, as assessed by MRS, in a cohort
of 232 United States euthyroid patients with type 2 diabetes [69]. However, the authors failed to
find significant associations between thyroid function tests and histological features of NAFLD in
a subset of patients submitted to liver biopsy [69]. By contrast, in a large longitudinal cohort study
of as many as 18,500 South Korean individuals, Lee et al. showed that both subclinical and overt
hypothyroidism were not significantly associated with an increased risk of incident NAFLD, as detected
by ultrasonography, independent of multiple cardio-metabolic confounders [68]. At present, four
published meta-analyses [77–80] further investigated the relationship between primary (subclinical and
overt) hypothyroidism and risk of NAFLD. In the first meta-analysis, including 14 observational
studies for a total of nearly 42,000 individuals, Jaruvongvanich et al. showed that NAFLD was not
associated with subclinical (random-effects OR 0.63, 95% CI 0.18–2.20), overt (random-effects OR 1.37,
95% CI 0.78–2.41), and unclassified hypothyroidism (random-effects OR 1.21, 95% CI 0.91–1.61) [77].
In contrast, in the subsequent meta-analysis by He et al., including 13 observational studies for a
total of approximately 37,000 individuals, both primary subclinical and overt hypothyroidism were
associated with an increased risk of prevalent NAFLD, independent of several metabolic confounders
(random-effects OR 1.52, 95% CI 1.24–1.87) [78]. Again, in a recent meta-analysis of 12 cross-sectional and
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three longitudinal studies for a total of 44,140 individuals, both subclinical and overt hypothyroidism
were independently associated with an increased risk of prevalent NAFLD (random-effects OR 1.42,
95% CI 1.15–1.77) [79]. However, when the authors meta-analyzed the data from the three longitudinal
studies, they found that subclinical hypothyroidism was not associated with an increased risk of
incident NAFLD over a median follow-up of five years (random-effects hazard ratio 1.29, 95% CI
0.89–1.86) [79]. More recently, the meta-analysis by Guo et al., including 26 observational studies for a
total of 61,548 individuals, documented that patients with NAFLD had significantly higher TSH levels
than those without NAFLD, and that unclassified hypothyroidism was significantly associated with an
increased risk of prevalent NAFLD [80].
With regard to the conflicting results found in observational studies [53–76] (Table 1), important
differences in terms of study design, population characteristics, definition of hypothyroidism, and
diagnosis of NAFLD are the most plausible explanations accounting for variable and inconsistent
findings among the published studies. With regard to the meta-analyses [77–80], the divergent findings
may be due to the use of different criteria for inclusion and exclusion of the studies, as well as to the
presence of high statistical heterogeneity, which may indirectly reflect the aforementioned differences
among the published observational studies.
Collectively, the currently available data [53–80] indicate that a significant and independent
association between subclinical and overt hypothyroidism and risk of NAFLD remains to be conclusively
proven. Large, prospective studies of well-characterized cohorts of patients (i.e., using a clear and
consistent diagnostic definition of both hypothyroidism and NAFLD) are eagerly awaited.
3.2. Putative Pathophysiological Mechanisms Linking Hypothyroidism with NAFLD
To date, the biological mechanisms responsible for the development and the progression of
NAFLD in individuals with hypothyroidism are incompletely understood. That said, the potential
mechanisms linking hypothyroidism to NAFLD include metabolic syndrome, dyslipidemia, insulin
resistance, oxidative stress, and direct action of TSH on the hepatocytes [19,49,81].
In healthy individuals, the thyroid gland produces two hormones (i.e., thyroxine and
triiodothyronine) which, acting through thyroid hormone receptors α and β, play a critical role
in cell differentiation during development and help maintain thermogenic and metabolic homeostasis
in adults [47].
Individuals with either subclinical or overt hypothyroidism often exhibit features of the metabolic
syndrome, such as overweight/obesity, impaired fasting glucose, and atherogenic dyslipidemia [47].
In this context, we highlight that NAFLD typically occurs in close association with impaired glucose and
lipid metabolism, as well as perturbed energy homeostasis [14,82], thereby justifying a close connection
between hypothyroidism and NAFLD. In fact, as experimentally documented, overweight/obesity per
se may blunt the effects of thyroid hormones on the liver, by profoundly affecting glucose and lipid
metabolism and energy homeostasis [19,49,81]. In addition, hypothyroidism is also associated with
atherogenic dyslipidemia (i.e., hypertriglyceridemia, increased plasma levels of low-density lipoprotein
(LDL)-cholesterol and very low-density lipoprotein (VLDL)-cholesterol, reduced plasma levels of
high-density lipoprotein (HDL)-cholesterol, and elevated apolipoprotein (apo)B lipoproteins) [82].
Hence, it is possible to speculate that hypothyroidism may further exacerbate NAFLD-associated
dyslipidemia, which may also be worsened by insulin resistance [19,81].
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Table 1. Observational studies and meta-analyses assessing the relationship between (subclinical and overt) hypothyroidism and risk of nonalcoholic fatty liver
disease (NAFLD; ordered by publication year and study design).
Ref. Study Population
Thyroid Function
Tests—Definition of
Hypothyroidism
NAFLD Diagnosis;
Prevalence of
NAFLD
Adjustments Main Findings
Observational studies
[53]
Case-control study:
174 US patients with NASH and
442 age-, sex-, race-, and
BMI-matched controls
Hypothyroidism was defined by
the self-reported use of
levothyroxine
Biopsy Diabetes, dyslipidemia,hypertension
Hypothyroidism was
independently associated with
an increased risk of NASH
[54] Cross-sectional study:878 Chinese elderly individuals TSH, FT4, and FT3
USG; 26% with
NAFLD
Age, BMI, waist circumference,
triglyceride, fasting glucose,
uric acid, creatinine
FT4 levels were independently
associated with an increased
risk of NAFLD
[55] Cross-sectional study:1322 Chinese individuals
Hypothyroidism was defined as
TSH levels >2.5 mIU/L
USG; 25% with
NAFLD
Age, sex, BMI, body fat,
triglycerides, systolic blood
pressure, diastolic blood
pressure, fasting glucose
Hypothyroidism was not
independently associated with
an increased risk of NAFLD
[56]
Population-based study
(Study of Health in Pomerania):
3661 German individuals
Subclinical hypothyroidism was
defined as TSH >3 mIU/L and
normal FT4; overt hypo thyroidism
was defined as TSH >3 mIU/L and
FT4 <7 pmol/L
USG; 16% with
NAFLD
Age, waist circumference,
physical activity, alcohol intake,
food intake pattern
Hypothyroidism was not
independently associated with
an increased risk of NAFLD.
Contrariwise, serum FT4 levels
were inversely associated with
NAFLD
[57]
Case-control study: 246 US
patients with biopsy-proven
NAFLD and 430 age-, sex-,
race-, and BMI-matched
controls
Hypothyroidism was defined by
the self-reported use of
levothyroxine
Biopsy Alcohol use
Hypothyroidism was
independently associated with
an increased risk of NAFLD
[58] Cross-sectional study:4648 South Korean adults
Subclinical hypothyroidism was
defined as TSH ≥4.1 mIU/L and
normal FT4; overt hypothyroidism
was defined as FT4 <0.7 ng/dL
USG; 25% with
NAFLD
Age, sex, BMI, waist
circumference, lipids
hypertension, diabetes
Subclinical and overt
hypothyroidism were
independently associated with
an increased risk of NAFLD
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Table 1. Cont.
Ref. Study Population
Thyroid Function
Tests—Definition of
Hypothyroidism
NAFLD Diagnosis;
Prevalence of
NAFLD
Adjustments Main Findings
[59]
Prospective case-control study:
327 Chinese patients with
subclinical hypothyroidism and
327 age-, sex-, and
BMI-matched euthyroid
controls
Subclinical hypothyroidism was
defined as TSH ≥4.5 mIU/L and
normal FT4 levels
USG; 15% of
individuals developed
NAFLD over a median
follow-up of ~5 years
Waist circumference, systolic
blood pressure, diastolic blood
pressure, lipids, fasting glucose
Subclinical hypothyroidism
was independently associated
with an increased risk of
NAFLD during the follow-up
[60]
Cross-sectional study: 69 Italian
euthyroid patients with
biopsy-proven NAFLD
TSH
Biopsy; 44 patients
had NASH, whereas
25 patients had only
steatosis
Age, sex, BMI, HOMA
TSH levels were independently
and positively associated with
an increased risk of NASH
[61] Cross-sectional study:832 Iranian healthy individuals
Subclinical hypothyroidism was
defined as TSH >5.2 mIU/L and
normal FT4 levels; overt
hypothyroidism was defined as
TSH >5.2 mIU/L and
FT4 <11.5 pmol/L
USG; 15% with
NAFLD None
Subclinical and overt
hypothyroidism were not
independently associated with
an increased risk of NAFLD
[62]
Cross-sectional study:
753 Mexican adults from the
Genetics of Atherosclerotic
Disease study
Subclinical hypothyroidism was
defined as TSH >4.5 mIU/L and
normal FT4 levels
Computed
tomography; 31%
with NAFLD
None
Subclinical hypothyroidism
was not independently
associated with an increased
risk of NAFLD
[63]
Cross-sectional study:
739 Chinese euthyroid
individuals
TSH, FT4 USG; 26% withNAFLD
Age, sex, BMI, smoking status,
systolic blood pressure,
diastolic blood pressure,
lipids, FT3
TSH and FT4 levels were
independently associated with
an increased risk of NAFLD
[64] Cross-sectional study:2576 euthyroid South Koreans TSH, FT4, FT3
USG; 38% with
NAFLD
Age, sex, smoking status,
hypertension, fasting glucose,
lipids, creatinine, uric acid
FT3 levels, but not TSH and FT4
levels, were independently
associated with an increased
risk of NAFLD
[65]
Cross-sectional study:
1154 Chinese with chronic
hepatitis B
Subclinical hypothyroidism was
defined as serum TSH >5.3 mUI/L
and normal FT4 levels, whereas
overt hypothyroidism was defined
as serum FT4 level <7.9 pmol/L and
TSH >5.3 mIU/L
Biopsy; 23% with
NAFLD Age, sex
TSH levels were independently
and positively associated with
an increased risk of NAFLD
Int. J. Mol. Sci. 2019, 20, 2841 10 of 34
Table 1. Cont.
Ref. Study Population
Thyroid Function
Tests—Definition of
Hypothyroidism
NAFLD Diagnosis;
Prevalence of
NAFLD
Adjustments Main Findings
[66]
Case-control study:
500 biopsy-proven NAFLD
Indians and 300 age-, sex-, and
BMI-matched controls
Hypothyroidism was defined by
the self-reported use of
levothyroxine
Biopsy Age, sex, BMI, transaminases
Hypothyroidism was
independently associated with
an increased risk of NAFLD
[67] Population-based study:1276 Germans
Subclinical hypothyroidism was
defined as TSH ≥3.4 mIU/L and
normal FT4 levels; overt
hypothyroidism was defined as
total T4 levels <12.8 pmol/L and
TSH levels ≥3.4 mIU/L
USG; 25% with
NAFLD
Age, sex, BMI, waist
circumference
Subclinical and overt
hypothyroidism were not
independently associated with
an increased risk of NAFLD
[68]
Longitudinal study:
18,544 healthy South Koreans
NAFLD-free at baseline
Subclinical hypothyroidism was
defined as TSH >4.2 mIU/L normal
FT4 levels; overt hypothyroidism
was defined as TSH >4.2 mIU/L
and FT4 <0.9 ng/dL
USG; 2348 individuals
developed incident
NAFLD during a
mean follow-up of
4 years
Age, sex, BMI, metabolic
syndrome
Subclinical and overt
hypothyroidism were not
independently associated with
an increased risk of NAFLD
[69] Cross-sectional study: 232 USAeuthyroid patients with T2D FT4
MRS; liver biopsy was
performed in patients
with a diagnosis of
NAFLD; 63% with
NAFLD
Age, BMI, hemoglobin A1c
FT4 levels were significantly
associated with hepatic
triglyceride. However, no
associations between thyroid
function tests and liver
histological parameters (such as
inflammation, hepatocyte
ballooning, and advanced
fibrosis) were observed
[70]
A population-based,
prospective cohort study
(the Rotterdam study):
9419 Dutch euthyroid
individuals
Subclinical hypothyroidism was
defined as serum TSH levels
>4.0 mIU/L and normal FT4; overt
hypothyroidism was defined as
serum TSH >4.0 mIU/L and FT4
levels <0.8 ng/dL
Fatty liver index at
baseline; USG and
Fibroscan® at
follow-up; 13% of
participants
developed incident
NAFLD over a median
follow-up of 10 years
Age, sex, BMI, alcohol intake,
smoking status, follow-up time,
use of lipid-lowering agents,
lipids, hypertension, diabetes
Compared to euthyroidism, any
form of hypothyroidism was
associated with an increased
risk of NAFLD. Moreover,
subclinical and overt
hypothyroidism were
associated with an increased
risk of liver fibrosis as detected
by Fibroscan®
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[71] Cross-sectional study:115 Turkish individuals FT3/FT4 ratio
USG; 60% with
NAFLD
Waist circumference,
lipids, uric acid, HOMA
FT3/FT4 ratio was
independently associated with
an increased risk of NAFLD
[72]
Population-based study
(Lifelines Cohort Study):
20,289 Dutch euthyroid
individuals
TSH, FT4, FT3 FLI (≥60); 21% withNAFLD Age, sex
FLI ≥60 was independently
associated with higher FT3 and
lower FT4 levels
[73] Cross-sectional study:580 Filipino adults
TSH >4.5 mIU/L without previous
history of thyroid disease
USG; 48% with
NAFLD None
NAFLD was not independently
associated with TSH levels
[74]
Case-control study 100 Indian
adult non-obese hypothyroid
patients and 100 age-, sex-, and
BMI-matched euthyroid
controls
Subclinical hypothyroidism was
defined as serum TSH levels
≥4.1 mIU/L and normal FT4 levels,
whereas overt hypothyroidism was
defined as serum TSH levels
≥4.1 mIU/L and FT4 levels
<0.7 ng/dL
USG; 42% with
NAFLD None
NAFLD was diagnosed in
30 patients with hypothyroid
and in 12 controls
[75]
Cross-sectional study:
425 South Koreans with
biopsy-proven NAFLD
Subclinical hypothyroidism was
defined as serum TSH >4.5 mIU/L
and normal FT4
Biopsy
Age, sex, BMI, smoking status,
hypertension, diabetes, lipids,
visceral adipose tissue area,
HOMA-IR
Subclinical hypothyroidism
was independently associated
with an increased risk of NASH
and advanced fibrosis
[76]
Population-based study:
3452 Koreans from Korea
National Health and Nutrition
Examination Survey 2013
to 2015
Subclinical hypothyroidism was
defined as a serum TSH levels
>6.7 mIU/L with serum FT4 within
a normal range
Hepatic steatosis
index (≥36)
Age, smoking status, physical
activity, income, MetS, waist
circumference, lipids, systolic
blood pressure, diastolic blood
pressure, fasting glucose, urine
iodine, thyroid peroxidase
antibodies
Subclinical hypothyroidism
was independently associated
with an increased risk of
NAFLD in males, but not in
females
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Meta-analyses
[77] 14 observational studies for atotal of 42,143 individuals
Self-reported history of
hypothyroidism with use of
levothyroxine replacement therapy
or by presence of abnormal thyroid
function tests
Imaging and biopsy Multiple demographic andclinical variables
NAFLD was not independently
associated with
hypothyroidism
[78] 13 observational studies for atotal of 37,194 individuals
Self-reported history of
hypothyroidism with use of
levothyroxine replacement therapy
or by presence of abnormal thyroid
function tests
Liver enzymes,
imaging, and biopsy
Multiple demographic and
clinical variables
Hypothyroidism was
independently associated with
an increased risk of NAFLD
[79]
12 cross-sectional and
3 longitudinal studies for a total
of 44,140 individuals
Self-reported history of
hypothyroidism with use of
levothyroxine replacement therapy
or by presence of abnormal thyroid
function tests
Imaging and biopsy Multiple demographic andclinical variables
Hypothyroidism was
independently associated with
an increased risk of prevalent
NAFLD. Meta-analysis of data
from 3 longitudinal studies
documented that subclinical
hypothyroidism was not
independently associated with
an increased risk of incident
over a median follow-up of
5 years
[80] 26 observational studies for atotal of 61,548 individuals
Self-reported history of
hypothyroidism with use of
levothyroxine replacement therapy
or by presence of abnormal thyroid
function tests
Imaging, FLI, and
biopsy
Multiple demographic and
clinical variables
NAFLD patients had
significantly higher TSH levels
compared to controls. In
addition, hypothyroidism was
significantly associated with the
risk of NAFLD
Abbreviations: BMI, body mass index; FLI, fatty liver index; FT3, free triiodothyronine; FT4, free thyroxine; HOMA, homeostatic model assessment; IR, insulin resistance; NAFLD,
nonalcoholic fatty liver disease; MetS, metabolic syndrome; MRS, magnetic resonance spectroscopy; NASH, nonalcoholic steatohepatitis; T2D, type 2 diabetes; TSH, thyroid-stimulating
hormone; USA, United States of America, USG, ultrasonography.
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Hypothyroidism is often associated with insulin resistance [19,51,81]. Preliminary evidence
suggests that elevated levels of certain adipocytokines [e.g., leptin, visfatin, tumor necrosis factor-α
(TNF-α), and interleukin-1] and increased oxidative stress, occurring during some conditions of
hypothyroidism, may concur with the development of insulin resistance [19,49,81]. Alterations in
specific cytokine levels and markers of oxidative stress, including reactive oxygen species (ROS)
and markers of lipid peroxidation, are shared features which are often observed in patients with
hypothyroidism [19,81], as well as in those with NAFLD [82], thus representing a further potential
pathophysiological mechanism underpinning the association between hypothyroidism and NAFLD.
In addition to the adverse effects of decreased serum thyroid hormones on hepatic glucose and lipid
metabolism, and potentially explaining the epidemiological finding that also subclinical hypothyroidism
may be sufficient to increase the risk of NAFLD, elevated serum TSH per se may promote the
development of NAFLD by stimulating hepatic de novo lipogenesis [19,49,81]. The biological activity
of TSH is mediated by its specific interaction with the thyrotropin receptor, which is not only expressed
on the membrane of thyroid follicular cells, but also in several extra-thyroidal tissues and cells,
including the hepatocytes [81]. Interestingly, increasing TSH concentrations may directly induce
NAFLD by increasing the intra-hepatocytic triglyceride content [19,81,83]. The molecular mechanism
underlying the hepatic steatogenesis induced by increasing TSH levels include activation of hepatic
sterol regulatory element-binding transcription factor 1 (SREBP-1c) via the cyclic AMP (cAMP)/protein
kinase A (PKA)/peroxisome proliferator-activated receptor-α (PPARα) pathway associated with
decreased AMP-activated protein kinase (AMPK), which further increases the expression of genes,
finally leading to enhanced steatogenesis [49,81,84].
3.3. Diagnosis and Management of NAFLD in Patients with Hypothyroidism
Given that hypothyroidism is often associated with features of the metabolic syndrome [19] and
that NAFLD is bi-directionally and mutually associated with the metabolic syndrome [79], a strong
consideration for NAFLD should be given to patients with hypothyroidism, especially whenever they
are overweight or obese [62,79]. However, we highlight that this topic is not covered by guidelines
issued by scientific societies; therefore, the aforementioned statement, which is strongly supported by
epidemiological evidence, mirrors the opinions of the authors.
Replacement therapy with levothyroxine, the standard treatment of hypothyroidism, is associated
with a significant decrease in BMI and serum lipids [47]. To date, there is scarce information on whether
treatment of hypothyroidism with levothyroxine is also able to improve NAFLD. In a post hoc analysis
of a randomized controlled trial, involving 360 patients with subclinical hypothyroidism, the treatment
with levothyroxine proved beneficial on serum liver enzyme levels and ultrasound-diagnosed NAFLD
after a 15-month period [85]. In a recent phase IIb single-arm trial, involving 20 euthyroid patients
with type 2 diabetes and NAFLD, the administration of low-dose levothyroxine for 16 weeks was
associated with a significant reduction of the intra-hepatic fat content, as assessed with MRS [86].
A small multicenter, double-blind, randomized, placebo-controlled phase 2 trial is ongoing to evaluate
the efficacy and safety of a highly selective liver-directed, thyroid hormone receptor-β agonist, namely
MGL-3196, in patients with biopsy-proven NASH [79]. However, at present, all these data are heavily
insufficient to recommend the prescription of levothyroxine in (a subset of) patients with primary
NAFLD. Therefore, additional clinical trials with liver histology endpoints are required to firmly
establish the potential benefits of the use of either levothyroxine or thyroid hormone receptor agonists
in patients with primary NAFLD.
Finally, specific lifestyle modifications (together with replacement therapy with levothyroxine)
are strongly recommended for patients with hypothyroidism, NAFLD, and metabolic syndrome
features. By contrast, the use of insulin sensitizers and antioxidants was never studied in this subtype
of patients and, to date, no available guideline regarding NAFLD or hypothyroidism addresses this
emerging aspect.
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4. Hypogonadism
4.1. Definition and Epidemiological Grounds
Irrespective of its variable underlying pathophysiological mechanisms, hypogonadism defines
the presence of reduced sex hormone concentrations in either sex [87]. Thus, while all types of
hypogonadism invariably result in low sex hormone levels, the clinical scenario is highly variable as a
function of the specific etiology (Table 2) [87]. Despite such a tremendous phenotypic variability, the
development and progression of NAFLD are common denominators of hypogonadism, independent
of sex and etiology.
Table 2. Main causes of hypogonadism (modified from Mintziori et al. [87]).
Primary (hypergonadotropic)
Congenital anatomical abnormalities of the gonads
Castration
Specific syndromes (e.g., Turner’s syndrome; Alstrom’s syndrome; Kallmann syndrome)
Drugs (e.g., antiandrogens, antiestrogens, chemotherapy)
Radiation
Hemochromatosis
Autoimmune
Secondary to pituitary/hypothalamic failure (hypogonadotropic)
Congenital
Tumor
Trauma
Radiation
Functional
As shown in Table 3, a growing number of studies support a strong and bi-directional association
between NAFLD and hypogonadism in both men and women [88–102].
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Table 3. Epidemiological evidence supporting the notion that patients with hypogonadism are at higher risk of NAFLD.
Ref. Study Characteristics Diagnosis of NAFLD Main Findings
Hypogonadism in men
[88] A cohort of 117 hypogonadic men (34–69 years), who weretreated with HRT (testosterone undecanoate for 1 year) ALT, AST, and CRP
HRT was associated with a significant reduction in adiposity measures, lipid
profile, and rate of individuals who met the criteria of the MetS. Steatosis
was strongly associated with all components of the MetS and RLE, which
were associated with higher plasma CRP concentrations, significantly
decreased following 1-year HRT
[89]
1944 non-drinking men submitted to repeated liver
ultrasonography over a median 4.2-year period, with
available baseline serum TT level were evaluated
Ultrasonography
Baseline levels of TT were significantly lower in NAFLD individuals in
cross-sectional analyses. However, TT level was not independently
associated with either development or regression of NAFLD during
follow-up
[90]
Retrospective study comparing 75 Chinese IHH men
(mean age 21.4 ± 3.8 years, range 17–30 years) to 135 age-
and sex-matched healthy controls
Ultrasonography
Compared to healthy controls, IHH men had higher serum ACTH levels,
lower cortisol levels, deranged glycolipidic profile and a higher prevalence
of NAFLD. NAFLD was independently associated with ACTH levels
[91]
55 consecutive men with chronic SCI admitted to a
rehabilitation program were submitted to
clinical/biochemical evaluations and liver ultrasonography
Ultrasonography
NAFLD was diagnosed in 49% of cases. TT and FT levels were
independently associated with NAFLD; the risk of NAFLD increased by 1%
for each decrement of 1 ng/dL of TT and of 3% for each decrement of
1 pg/mL of FT
[92]
Out of 380,669 men with histologically proven prostate
cancer, 31,117 elderly men who received ADT were
identified by using a representative cancer registry.
Individuals with metastatic disease, pre-existent MetS,
diabetes, preexisting liver disease, or a history of
alcoholism/ alcohol related disorders were excluded
Diagnostic and procedural codes
from physician office or inpatient visits
Elderly men submitted to ADT were more likely to be diagnosed with
NAFLD, cirrhosis, liver necrosis, and any liver disease
Hypogonadism in women
[93]
Retrospective analysis of serum liver enzymes in 80 women
with TS, followed by a prospective study in 20 women with
TS following 3 months on-and-off HRT
GGT, AST, and ALP 44% of women with TS had RLE. HRT resulted in a significant reduction inserum liver enzymes without improving serum protein concentrations
[94]
Prospective, double-blind, RCT vs. placebo recruiting
5408 women who underwent hysterectomies and enrolled
into the multicentric Italian tamoxifen
chemoprevention trial
NAFLD was suspected based on de novo
incident chronic unexplained
hyper-transaminasemia (× 1.5 n.v.) over
a 6-month period, in the absence of
competing etiologies and confirmed with
ultrasonography. NAFLD women
defined as above were offered
confirmative liver biopsy
52 out of 64 women who met the predefined criteria in the course of
follow-up developed suspected US-confirmed NAFLD: 34 on tamoxifen vs.
18 on placebo, HR = 2.0 (95% CI 1.1–3.5; p = 0.04). Further to tamoxifen,
overweight (HR 2.4, 95% CI 1.2–4.8), obesity (HR 3.6, 95%CI 1.7–7.6),
hypercholesterolemia (HR 3.4, 9%% CI 1.4–7.8), and hypertension (HR 2.0,
95% CI 1.0–3.8) were associated with increased risk of incident NAFLD. Out
of 20 women submitted to LB, 15 had mild-to-moderate NASH
(12 tamoxifen vs. 3 placebo), and 5 had simple steatosis (1 tamoxifen vs.
4 placebo). None developed cirrhosis over a mean 8.7-year follow-up
Int. J. Mol. Sci. 2019, 20, 2841 16 of 34
Table 3. Cont.
Ref. Study Characteristics Diagnosis of NAFLD Main Findings
[95] 50 women with T2D entered a double-blind, RCT of HRTvs. placebo AST, ALT, GGT, and ALP
Compared to those randomized to placebo, women randomized and
compliant to HRT (n = 19) had significant reductions in serum liver enzymes
[96]
Serum liver enzymes were assessed in 169 women (14 with
TS and 11 controls with hypogonadism) on HRT with oral
E2
GGT, ALT, ALP, albumin, and bilirubin
The prevalence and incidence rates of RLE among women with TS were 91%
and 2.1% per year, respectively. RLE were associated with total cholesterol
and BMI, and reversed by increasing doses of HRT
[97] 218 women with TS (mean age 33 ± 13, range 16–71 years)from outpatient clinics at Swedish university hospitals.
AST, ALT, ALP, GGT, serology for viral
hepatitis and liver-specific
auto-antibodies
36% of TS women had one or more RLE; the most prevalent was serum GGT
level, which was independently associated with total cholesterol both at
baseline and at 5 years. Liver histology findings in 6 TS women submitted to
LB included cholangitis (n = 1), hepatitis C (n = 1), steatosis (n = 2), and
normal (n = 2). Withdrawal of estrogen substitution did not influence serum
liver enzymes
[98]
This Mexican cross-sectional study compared
anthropometric, metabolic, hormonal (serum estradiol and
cortisol concentrations), and biochemical variables in
93 women with NAFLD and as many NAFLD-free controls
Ultrasonography and transient
elastography; APRI, NFS
The prevalence of NAFLD in premenopausal, post-menopausal, and PCOS
patients was 32.2, 57.9, and 62%, respectively. Age, adiposity measures,
fasting glucose, HOMA-IR, and insulin were significantly higher in NAFLD
patients. Compared to NAFLD women, those NAFLD-free women had
significantly higher levels of serum E2
[99]
541 individuals with biopsy-proven NASH were recruited.
LRA was used to determine the association among sex,
menopause, and severity of hepatic fibrosis
Liver biopsy
Compared to pre-menopausal women, men and post-menopausal women
had a higher risk of advanced liver fibrosis suggesting that estrogens may
protect from fibrosis
[100]
Survey of questionnaires referring to 492 patients with TS
(age 17.1–42.5 years) administered by attending physicians
throughout Japan. For comparison purposes, data from the
National Health and Nutrition Survey were used
Liver dysfunction was defined as AST
≥41 U/L, ALT ≥36 U/L, or GGT ≥60 U/L
Women with TS tend to become obese from young ages (15–39 years).
Compared to the Japanese general female population, women with TS had
higher prevalence rates of diabetes, hypertension, dyslipidemia, and liver
dysfunction which were associated with increasing BMI rather
than karyotypes
[101]
Retrospective analysis of incident fatty liver and/or RLE
during SERM treatment in 1061 women who were treated
for breast cancer
Imaging and/or ALT
SERM treatment was independently associated with an increased the risk of
incident raised serum ALT levels and/or fatty liver. Consistently, SERM
discontinuation was associated with normalization of raised ALT levels in
virtually all cases. No cases of liver-related death/ progression to cirrhosis
were registered
[102]
Analysis of data from 488 post-menopausal women with
histologically proven NAFLD and self-reported
information on age at menopause
Liver histology In post-menopausal women with NAFLD, the duration of estrogendeficiency affected risk of liver fibrosis.
Abbreviations: ADT, androgen deprivation therapy; ALP, alkaline phosphatase; ALT, alanine aminotransferase; APRI, AST-to-platelet ratio index; AST, aspartate aminotransferase; BMI,
body mass index; CI, confidence intervals; CRP, C-reactive protein; E2, 17-β-estradiol; FL, fatty liver; FT, free testosterone; GGT, γ-glutamyl transferase; HR, hazards ratio; HRT, hormone
replacement therapy; HWR, hip-to-waist ratio; IHH, idiopathic hypogonadotropic hypogonadism; LB, liver biopsy; LRA, logistic regression analysis; MetS, metabolic syndrome; NAFLD,
nonalcoholic fatty liver disease; NFS, NAFLD fibrosis score; RCT, randomized controlled trial; RLE, raised liver enzymes; SCI, spinal cord injury; SERM, selective estrogen receptor
modulator; TS, Turner syndrome; TT, total testosterone; US, ultrasound.
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With regard to men, patients with NAFLD exhibit reduced serum testosterone levels in
cross-sectional studies [89,91], and the lower the testosteronemia, the higher the risk of NAFLD [91].
Moreover, hormone replacement therapy improves NAFLD and features of the metabolic syndrome in
hypogonadic men [92]. Finally, preliminary evidence also suggests that men rendered hypogonadal by
androgen deprivation therapy for prostate cancer have a higher risk of progressive NAFLD [92].
With regard to women, the prototypic state of female hypogonadism, i.e., the Turner syndrome,
is associated with an increased prevalence of raised serum liver enzymes, surrogate indices of
NAFLD [93–100]. Moreover, it is known that conditions of estrogen deficiency, which may occur either
physiologically in post-menopausal women or in hypogonadism-related diseases, are associated with
a higher prevalence of NAFLD and advanced liver fibrosis [101,102]. The risk of advanced hepatic
fibrosis is associated with longer duration of estrogen deficiency [102].
Post-menopausal status is deemed to be a risk factor for the development and progression of
NAFLD in humans [103]. This statement is based on a consistent line of evidence. For example, a
case-control study comparing 712 women submitted to oophorectomy to 163 control women found
that oophorectomy was an independent predictor of NAFLD [104]. Another large study conducted
in 9360 women not only found that the prevalence of NAFLD increased in parallel with increasing
age, but also that the prevalence rates of NASH (assessed with a BMI/age/alanine aminotransferase
(ALT)/triglyceride (BAAT) index ≥3) were 13.2% vs. 14.9% in women >55 years and obese women with
NAFLD, respectively, thus suggesting that post-menopausal age and obesity exert almost the same
adverse impact on the risk of developing NASH [105]. At variance with the above studies, in which
NAFLD and NASH were diagnosed on a non-invasive basis [106,107], Yang et al., by evaluating data
of 541 adults with biopsy-proven NASH, found that men had a higher risk of having more severe
liver fibrosis than pre-menopausal women [99]. However, this advantage was lost by women in
post-menopausal age whose severity of liver fibrosis was similar to men, suggesting that estrogen
protects from hepatic fibrosis. Direct evidence for a beneficial effect of estrogen on the liver was
provided by Kamada et al. [107]. These authors reported that ovariectomized mice fed a high-fat
and high-cholesterol diet had more severe hepatic histological injury owing to increased intrahepatic
infiltration of macrophages, enhanced expression of monocyte chemoattractant protein-1, and increased
expression of hepatic inflammatory genes compared to sham-operated controls fed the same diet [107].
Treatment with estrogen was able to improve all the above changes [107].
It is known that treatment with the anti-estrogen tamoxifen may increase the risk of NAFLD and
NASH in hysterectomized women [94], and that hormonal replacement therapy is associated with a
significant improvement in serum liver enzymes in post-menopausal women with type 2 diabetes [95].
Collectively, these findings suggest that estrogens may protect from the development and progression
of NAFLD [103,108].
4.2. Pathophysiological Mechanisms Linking Hypogonadism with NAFLD
In health states, gonadal hormones play a key role in regulating total body fat and its regional
distribution, as well as insulin sensitivity and glucose homeostasis. Conversely, the deficiency of
such hormones, such as seen in hypogonadal states, is typically associated with either the full-blown
metabolic syndrome or its individual features, notably including the molecular effectors of hepatic
steatogenesis, both in experimental disease and in human NAFLD [109].
The biological mechanisms accounting for the association between hypogonadism and NAFLD
are very complex and likely to be variable according to the individual categories of hypogonadism.
However, some common pathogenic mechanisms may be identified, which closely mirror the biological
end-result of the defective hormones (Table 4) [108]. Given that total and regional adiposity
(i.e., subcutaneous versus visceral adipose tissue) may critically depend on sex hormones [103],
it is clear that hypogonadism will exhibit those features of either overall or visceral obesity, which are
known to increase the risk of development and progression of NAFLD via impaired glucose tolerance,
hypertension, and atherogenic dyslipidemia [17].
Int. J. Mol. Sci. 2019, 20, 2841 18 of 34
Table 4. Metabolic effects of sex hormones (modified from Shen et al. [108]).
Glucose Metabolism Lipid Metabolism
Estrogen ↑ Insulin clearance ↑ Glycogen storage ↑ Lipolysis ↑ Cholesterolremoval
↓Gluconeogenesis ↓Lipogenesis↓Lipid uptake
↓Cholesterol
synthesis
Androgen ↑ Insulin receptor ↑ Glycogensynthesis
↑ Cholesterol
uptake
↑ Cholesterol
synthesis
↓Glucose uptake ↓Lipogenesis ↓Cholesterolremoval
In addition to these common pathophysiological features, some specific mechanisms may also be
active in either sex. For example, estrogen deficiency in men results in the development of NAFLD
associated with typical features of the metabolic syndrome [110,111]. Moreover, compared to men,
women are physiologically more protected from liver injury associated with oxidative stress thanks
to the antioxidant properties of estrogen [112]. This accounts for the increased risk of NAFLD and
hepatic fibrosis in post-menopausal women. In rat models, the synthesis of fibroblast growth factor
(FGF)-21 declines after ovariectomy, thus contributing to the development of NAFLD [113].
Altered gut microbiota may be another potential factor linking acquired hypogonadism with
the development of NAFLD in animal models. Harada et al. reported that, in castrated male mice,
androgen deprivation was associated with both increased Firmicutes/Bacteroidetes ratio and number
of Lactobacillus species [114]. Intestinal dysbiosis also exacerbated the cardio-metabolic risk in a
sex-dependent manner only in male mice fed a high-fat diet, suggesting that dietary stimuli may
amplify cardio-metabolic risk factors via altered gut microbiota [113].
Dehydroepiandrosterone (DHEA), the most abundant steroid hormone, affects insulin resistance,
oxidative stress, metabolic homeostasis, and fibrogenesis [115]. Based on this biological background,
associated with the observation that NASH follows a rapidly progressive course toward cirrhosis in
patients with DHEA deficiency owing to panhypopituitarism, Charlton et al. were first in evaluating
serum levels of this hormone in fibrosing NASH [115]. Since this pioneering study, others tried to either
confirm or dispute this theory and, of the various studies which, over time, addressed this research
question (summarized in Table 5 [90,115–119]), all invariably found that biopsy-proven NASH with
fibrosis is associated with reduced serum sulfated DHEA (DHEA-S) levels [105].
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Table 5. Evidence for an association of low serum levels of sulfated dehydroepiandrosterone (DHEA-S) with histologically proven fibrosing NASH.
Ref. Method Findings Comment
[115]
Overall, 439 patients with biopsy-proven mild/advanced NAFLD were
enrolled in the USA
Simple steatosis and NASH with initial fibrosis (i.e., stages 0–2) were
categorized together as “mild NAFLD”
NASH with fibrosis stage 3–4 was defined as “advanced NAFLD”
DHEA-S was measured with ELISA.
Compared to patients with mild disease, individuals with advanced NAFLD
exhibited lower serum concentrations of DHEA-S
Decreasing DHEA-S paralleled increasing stages of fibrosis
All patients who had advanced NAFLD exhibited as low DHEA-S levels which
were compatible with adrenal insufficiency in the majority of cases
NASH with advanced stages of
fibrosis is strongly associated with
low serum concentrations of DHEA-S
[116]
Data from 133 Japanese patients with biopsy-proven NAFLD (90 with
NASH: 73 patients had fibrosis stage 0–2, and 17 had advanced disease
as defined by fibrosis stage 3 or 4) were compared to 399 sex- and
age-matched healthy controls
DHEA-S was measured by CEI
DHEA-S serum concentrations were not statistically different from those found in
the controls
Lower DHEA-S paralleled with increasing stages of fibrosis and this association
remained after adjustment for confounding factors (age, sex, and IR)
Low circulating DHEA-S could have
a causal role in the progression of
NAFLD to fibrosing NASH
[117]
69 Japanese men who had NAFLD diagnosed with ultrasonography
were extracted from a larger sample of 158 Japanese men who had
neither viral liver diseases nor an alcoholic intake >20 g/day
DHEA-S was measured by RIA
At multivariate regression analysis, serum ALT was positively correlated with
serum DHEA-S, serum triglyceride, and BMI
DHEAS levels are increased in
patients with NAFLD with elevated
ALT levels
[118]
160 individuals with morbid obesity were submitted to liver biopsy
which showed SS in 72, NASH with fibrosis stage 0–1 in 60, and NASH
with fibrosis stage ≥2 in 12 patients. 16 had normal liver histology
DHEA-S was measured by ELISA
With one exception, all patients with NASH and fibrosis stage 2–3 had low serum
DHEA concentrations, i.e., <123 µg/dL.
Low serum levels of DHEA are very
common among morbidly obese
individuals with NASH and
advanced fibrosis
[119]
This study enrolled (a) a training cohort of 44 patients with biopsy
proven NAFLD and (b) a validation cohort comprising 105 patients with
biopsy-proven NAFLD and 26 with biopsy-proven PBC patients.
Moreover, 48 age-matched healthy controls who had normal liver tests
and no infection with hepatitis viruses were evaluated
Metabolites with LMW were identified with capillary electrophoresis
and liquid chromatography with mass spectrometry
In the training cohort, increasing severity of hepatic fibrosis was associated with a
decrease of DHEA-S and etiocholanolone-S and an increase of 16-OH-DHEA-S.
In the validation cohort, the 16-OH-DHEA-S/DHEA-S ratio and
16-OH-DHEA-S/etiocholanolone-S ratio were also strongly associated with the
stage of fibrosis. Conversely, DHEA-S, etiocholanolone-S, and the two ratios were
not associated with the stage of fibrosis in patients with PBC
Disturbances in the hormonal profile
are a specific feature of NAFLD,
which could be exploited for
therapeutic purposes
[90]
Retrospective case-control study enrolling 75 Chinese men with IHH
and 135 age- and sex-matched healthy controls.
The diagnosis of presence/absence of NAFLD was based on
ultrasonography to which only 63 individuals with IHH were submitted
DHEA-S was measured by chemiluminescence
DHEA-S serum concentrations were significantly more elevated among those
22 patients with IHH and NAFLD than among those 41 with IHH without NAFLD
There is a complex interaction among
the HPA axis, testosterone deficiency,
and perturbed metabolic health
in men with IHH
Abbreviation: CEI, chemiluminescent enzyme immunoassay; DHEA-S, sulfated dehydroepiandrosterone; ELISA, enzyme-linked immunosorbent assay; Etiocholanolone-S, 5α-androstan-3β
ol-17-one sulfate; HPA, hypothalamic–pituitary–adrenal; IHH, idiopathic hypogonadotropic hypogonadism; IR, insulin resistance; LMW, low molecular weight; NASH, nonalcoholic
steatohepatitis; 16-OH-DHEA-S, hydroxy-dehydroepiandrosterone sulfate; PBC, primary biliary cholangitis; RIA, radioimmunoassay; SS, simple steatosis.
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4.3. Principles of Diagnosis and Management
4.3.1. Diagnosis
The diagnosis of hypogonadism-induced NAFLD requires a high index of suspicion in the
individual case. Although this topic is not specifically regulated by current guidelines, the exclusion of
other competing causes of (steatogenic) liver disease is a part of the general diagnostic philosophy of
NAFLD [38,120–122]. On the other side, it seems logical to propose that, in patients with hypogonadism,
a first-line non-invasive assessment of the liver should routinely be performed by the endocrinologist
in charge of the patient. This may be accomplished by using the same diagnostic approach suggested
under Section 2.4 and after exclusion of competing causes of liver disease before referring the patient
to the hepatologist whenever fibrosing liver disease is suspected.
4.3.2. Management
The general principles of treatment include lifestyle changes, namely dietary restrictions coupled
with physical exercise, as well as other interventions chiefly aimed at treating comorbid conditions [123].
The specific principles of treatment are usually differentiated on a sexual basis.
The treatment of choice in male hypogonadism is the administration of testosterone rather
than aromatase inhibitors, which raise plasma testosterone levels while reducing E2 [123].
Indeed, in men, circulating levels of E2 exceed those of post-menopausal women; estrogen receptors
are expressed in many target tissues, and E2 plays a key role in regulating endocrine axes, such as
hypothalamic–pituitary–testicular, as well as growth hormone insulin-like growth factor-1, in preserving
the reproductive function, bone health, body composition, carbohydrate homeostasis, and vasomotor
stability [124]. Since 2015, testosterone products have to be labeled with a warning on potential
cardiovascular risk associated with this hormone, despite the fact that this therapy may actually
improve such cardiovascular outcomes [125].
Hypogonadism in women is treated with estrogen replacement through a variety of strategies
spanning from treatment with low-dose transdermal E2, oral micronized E2, or per the intramuscular
route; after progestin is added, a pill containing both an estrogen and a progestin may be preferable
owing to the ease of its use [126].
In conclusion, we strongly suggest that patients with hypogonadism-induced NAFLD should be
managed jointly by the endocrinologist and the hepatologist with the specific aim of preventing the
progression of both liver-related complications and extra-hepatic manifestations of NAFLD [2,127].
The use of sex hormone replacement therapy in selected cases of primary NAFLD is an interesting topic
of research which requires specific experimental studies and clinical trials, and cannot be recommended
at present.
5. GH Deficiency
5.1. Epidemiology of GH Deficiency
GH and its chief mediator, insulin-like growth factor-1 (IGF-1), are mainly under control of the
hypothalamic–pituitary somatotropic axis, even if other elements are involved in their homeostasis
and secretion. GH and IGF-1, by regulating glucose and lipid metabolism, body composition,
and growth, exert a key metabolic role on the liver, adipose tissue, and skeletal muscle both in children
and adults [128,129]. Therefore, GH exerts many effects in different tissues, mediated by complex
mechanisms, either directly via interaction with GH receptor or indirectly via its mediator IGF-1 [13].
Specifically, in adult healthy subjects, GH promotes the release of free fatty acids (FFA), via lipolysis in
the visceral adipose tissue; moreover; GH also stimulates protein synthesis and exerts anabolic effects
on muscle and bone tissue, contributing to an increase in lean body mass, muscle strength, and bone
mineral density [130]. The effect of GH and its deficiency on glucose metabolism is quite intricate. It is
known that GH stimulates gluconeogenesis and glycogenolysis in the liver and inhibits glucose uptake
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in adipose tissue, contrasting insulin signaling. Unexpectedly, GHD determines insulin resistance
probably due to the increased FFA flux and glycogen synthesis inhibition, but the exact mechanisms
remain to be elucidated [129,130].
The actions of the GH–IGF-1 axis are regulated by a complex intracellular signaling pathway,
involving Janus kinase 2 (JAK-2) and signal transducer and the activation of activator of transcription
5 (STAT-5), with regulation of target genes leading to an improvement of systemic insulin resistance
and lipolysis in visceral adipose tissue [130]. As known, liver is the main tissue involved in IGF-1
production after GH secretion. IGF-1, after binding IGF-binding proteins and its specific receptors
(ubiquitously expressed), contributes to systemic metabolic effects, increasing GH action. However,
many other extra-hepatic tissues and the liver itself can produce IGF-1, where it exerts autocrine and
paracrine effects in a GH-independent manner [131]. Different elements, such as nutritional status,
protein and glucose intake, and inflammatory state, are involved in regulating the peripheral and
GH-independent production of IGF-1 [132].
GHD in adults (AGHD), in most cases due to either hypothalamic and pituitary lesions or their
treatment, leads to detrimental metabolic consequences typically involved in NAFLD pathogenesis,
such as visceral obesity, dyslipidemia, and insulin resistance, carrying an inherently increased
prevalence of metabolic syndrome [130], an increased risk of premature atherosclerosis, cardiovascular
morbidity/mortality, and poor quality of life [128,133]. Based on the finding that untreated AGHD
patients exhibit a metabolic syndrome-like phenotype, which is strongly and bi-directionally associated
with NAFLD, a potential association between GHD and NAFLD was suggested [134].
Confirming this suggestion, both NAFLD and metabolic syndrome are associated with lower serum
GH levels and lower GH and IGF-1 levels were consistently reported in NAFLD patients compared to
NAFLD-free controls [135–139]. Moreover, lower GH and IGF-1 levels are also associated with the
histological severity of NAFLD [139–141]. Consistently, in a cohort of patients with biopsy-proven
NAFLD, hepatic IGF-1 messenger RNA (mRNA) levels were significantly decreased in patients with
NASH compared to those with simple steatosis, and inversely associated with the degrees of hepatic
steatosis and inflammation [142].
Seen from another perspective, hypothalamic and pituitary disorders, including GHD, are also an
increasingly recognized risk factor for the development and progression of secondary forms of NAFLD,
which are not reversible following lifestyle changes [143–149]. Indeed, in the last decades, NAFLD
was increasingly diagnosed as a hepatic complication of GHD, carrying a high risk of progressing to
more severe forms of NAFLD and requiring liver transplantation (Table 6 [143–148]). In a retrospective
study, Adams et al. found a prevalence of NAFLD of approximately 2% in patients with hypothalamic
or pituitary disorders. Of concern, these patients developed progressive NAFLD, i.e., with histological
evidence of either fibrosis or cirrhosis, only a few years after the diagnosis [143]. Specifically, patients
with GHD had a 6.4-fold increased prevalence of NAFLD compared to age-, sex-, and BMI-matched
controls; in addition, almost all of a selected subgroup of GHD patients had histological evidence
of NASH [144]. In agreement, Ichikawa et al. found that, compared to patients with pituitary
dysfunction without GHD, those with GHD had a significantly increased risk of NAFLD [145]. In their
case-control study, Hong et al. found that the prevalence of NAFLD was significantly higher in men
with hypopituitarism than in healthy controls and that, in NAFLD patients, serum GH levels were
lower and inversely correlated with the severity of hepatic steatosis [146]. Conflicting with the findings
reported above, however, some studies found a similar prevalence of both NAFLD and MRI-assessed
hepatic fat content when comparing cohorts of patients with GHD to GHD-free control subjects [149].
Differences in demographic and anthropometric features among the various cohorts might potentially
account for these conflicting results [147,148]. The finding that GH replacement therapy induced a
small reduction of hepatic fat content in NAFLD patients with GHD [147] offers the reasonable hope
to resolve this ongoing scientific controversy by addressing this topic from a therapeutic perspective
thanks to adequately sized future large therapeutic trials.
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Table 6. Principal published studies evaluating the association of growth hormone deficiency (GHD)
with NAFLD.
Author, Ref. Method, Cohort, and Diagnostic Criteria Findings
[143]
Longitudinal cohort study.
879 patients with hypothalamic or pituitary dysfunction.
NAFLD diagnosis based on with imaging and liver enzyme
alteration. Liver biopsy was performed in a subgroup of 10
NAFLD patients
NAFLD was found in 21 patients with metabolic
syndrome-like phenotype (prevalence of 2.3%).
The majority of biopsy-proven NAFLD patients
exhibited advanced forms, i.e., cirrhosis and NASH
with fibrosis
[144]
Cross-sectional retrospective study.
66 adults with hypopituitarism and GHD compared to 83
age-, gender-, and BMI-matched healthy controls.
19 patients received GH replacement therapy according to
clinical recommendations.
GHD diagnosis based on insulin tolerance test or GH
releasing peptide-2 test.
NAFLD diagnosis based on ultrasound. Liver biopsy was
performed in 16 patients
NAFLD prevalence was significantly higher of 6.4-fold
in GHD group compared to healthy controls,
independently of obesity. Overweight and insulin
resistance were more prevalent in GHD group with
NAFLD. Histological NASH was found in 14 out of 16.
GHRT was associated with reduction of liver enzyme
and improvement of steatosis and fibrosis
[145]
Cross-sectional study.
18 adult patients with hypopituitarism, of these
13 with GHD.
NAFLD diagnosis based on computer tomography (CT)
(liver/spleen CT value <0.9)
Prevalence of hepatic steatosis higher in GHD subjects
compared to hypopituitaric subjects without GHD,
independently of BMI and triglycerides levels
[146]
Cross-sectional observational study.
34 Korean patients with hypopituitarism and 40 age- and
sex-matched lean healthy controls.
GHD defined as peak GH level of <3 ng/mL.
NAFLD diagnosis based on ultrasound
Prevalence of fatty liver was significantly higher in men
with hypopituitarism than controls. Among NAFLD
patients with hypopituitarism, GH levels were lower
and negatively correlated with degree of steatosis
[147]
Cross-sectional study.
28 patients with GHD and 24 age- and BMI-matched controls.
12 GHD patients evaluated longitudinally before and
6 months after start of GHRT.
GHD diagnosis based on GH response <3 mg/L after
glucagon stimulation.
NAFLD defined as MRI-assessed intrahepatic lipid content
(IHLC) > 5.6%
Although GHD patients exhibited higher visceral fat,
the 2 groups presented similar liver enzyme levels and
IHLC. GHRT was associated with reduction of
subcutaneous and visceral adipose tissue and, in those
with baseline high liver fat, with a positive trend in
reduction of IHLC
[148]
Cross-sectional study.
22 adult patients with GHD and 44 age-, gender-,
and BMI-matched healthy controls.
9 GHD patients received GHRT.
GHD diagnosis based on GH levels <7.8 mU/L after
glucagon stimulation test.
NAFLD diagnosis based on IHLC >5.56% assessed with
proton magnetic resonance spectroscopy (1H-MRS)
No significant difference in IHLC and prevalence of
hepatic steatosis was observed in the two groups.
In GHD patients receiving GHRT, no changes in IHLC
were observed
Abbreviations: NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; GH, growth hormone;
GHD, growth hormone deficiency; BMI, body mass index; GHRT, growth hormone replacement therapy; IHCL,
intrahepatic lipid content.
5.2. Pathophysiological Mechanisms Linking GHD with NAFLD
Based on the metabolic effects of the GH–IGF-1 axis on the adipose tissue and the liver, different
pathogenic mechanisms were suggested as a possible link between GHD and NAFLD [150,151],
notably including insulin resistance, which is a shared common denominator of both diseases. It was
repeatedly observed that mouse models with liver-specific deletion of GH receptor (GHRLD) develop
insulin resistance, hepatic steatosis, dyslipidemia, and increased de novo lipogenesis [152,153]. In a
cell culture model, Rufinatscha et al. demonstrated a decreased hepatic insulin sensitivity in GHR
knockdown hepatocytes, which was not completely reversed by IGF-1 administration, suggesting an
important role of GH on hepatic glucose metabolism [142]. The development of NAFLD in liver-specific
JAK2-deficient (JAK2L) [154] and liver-specific STAT5-deficient mice [155] highlights the importance
of the GH signaling pathway.
Furthermore, GHRLD mice also exhibit alterations in mitochondrial structure and function
and increased oxidative stress with enhanced production of ROS, which in turn further impairs
mitochondrial function. Interestingly, these hepatic modifications improve following the administration
of either GH or IGF-1, suggesting a GH-independent effect of IGF-1 on the liver [156,157]. In this
context, emerging data also suggest that melatonin (a pleiotropic hormone primarily known for its
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regulatory role in circadian rhythms, sleep, retinal functions, and the immune system) may have a
relevant role as a scavenger of ROS with antioxidant properties in individuals with features of the
metabolic syndrome [158]. Interestingly, new experimental studies also indicate that, in mouse liver,
melatonin is also needed for insulin-stimulated phosphatidylinositol 3-kinase (PI3K)–protein kinase B
activity. In rats, it seems to suppress the hepatic glucose production, and, in the human hepatocyte cell
line HepG2, it activates glycogen synthesis via a protein kinase C (PKC)ζ–AKT–glycogen synthase
kinase-3β (GSK3β) pathway [158]. Moreover, in animal models with high-fat diet (HFD)-induced
NAFLD, melatonin seems to be involved in reducing liver and mitochondrial alterations due to
oxidative stress and in improving steatosis and histological features [159].
Additionally, a systemic low-grade inflammatory state characterized by increased levels of
pro-inflammatory cytokines may also promote the development and progression of NAFLD in GHD
patients. In GHRLD mice, Fan et al. showed an increased hepatic expression of fibrogenic and
inflammatory genes, such as tumor necrosis-α (TNF-α) and C–C motif chemokine ligand 3 (CCL3) [152].
In humans, Takahashi et al. found a reduction in TNF-α and C-reactive protein after GH replacement
therapy [160]. Another biological activity of GH pertains to its control of hepatocyte proliferation, as
demonstrated by GHRLD mice exhibiting impaired hepatocyte regeneration. Instead, IGF-1 seems
to affect the biology of hepatic stellate cells by inducing their senescence and inactivation, thereby
limiting hepatic fibrogenesis [161].
5.3. Principles of Diagnosis and Management
Provocative tests of GH secretion are used to identify GHD, considering the pulsatile GH
secretion. The insulin tolerance test, deemed to be the standard test, and the GH-releasing hormone
(GHRH)-arginine test, well tolerated, are both used in clinical practice for the diagnosis of GHD.
The identification of GH cut-off values for a definite diagnosis of GHD is difficult owing to the lack
of normal ranges standardized according to demographic and anthropometric variables. However,
a cut-off of 4.1 g/L for the GHRH-arginine test and <5.1 g/L for the insulin tolerance test are considered
suggestive for GHD [162,163].
In contrast to pediatric populations, GH replacement therapy should be administrated only
in severe and symptomatic forms of AGHD, aiming at reducing visceral fat mass, improving
lipid profile, and decreasing cardiovascular morbidity [161]. Despite exerting many positive
metabolic effects, GH replacement therapy, however, is not indicated as a possible treatment for
NAFLD in AGHD patients [163]. About two decades ago, Takano et al. reported one of the first
cases of fatty liver significantly improving after GH replacement therapy in a young patient with
pan-hypopituitarism [164]. Subsequently, the role of GH replacement therapy in improving NAFLD
in AGHD patients was confirmed [164]. Indeed, GH replacement therapy reduces liver enzymes,
and improves hepatic steatosis and biomarkers of inflammation and fibrosis [164,165]. Furthermore,
the interruption of GH replacement therapy in adults with childhood onset GHD may increase the risk
of developing metabolic complications, including dyslipidemia and NAFLD, indirectly suggesting
that long-term GH replacement therapy plays a role in preventing cardio-metabolic risk [166,167].
However, considering the negative impact of weight gain on the efficacy of GH replacement
therapy [164], it can be hypothesized that other factors may potentially contribute to the progression
of NAFLD. Therefore, in GHD adult and pediatric subjects, GH replacement therapy covers a major
role in determining an improvement on clinical and histological features of NAFLD, confirming a
predominant role of GHD on the development of NAFLD [144,165]. Instead, lifestyle changes merely
contribute an additional effect to specific therapy, but they are unable to prevent the progression of
liver disease in this type of secondary NAFLD [144,149]. Moreover, patients with GHD often have
concomitant derangements of other endocrine pathways, such as thyroid, gonadal, and glucocorticoid
hormones, which may all play a major role in the development of secondary NAFLD and NASH via
obesity and insulin resistance [132].
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In conclusion, based on the evidence reported above, screening for NAFLD seems justified in all
patients with GHD. Although data are still controversial, considering its beneficial effects on insulin
resistance, inflammation, oxidative stress, and fibrosis, the administration of exogenous GH and
especially IGF-1 has a strong rationale and potential clinical applications in the treatment of NAFLD
secondary to hypothalamic–pituitary dysfunction(s). Conversely, whether and in which subset of
individuals with primary NAFLD hormone replacement therapy with GH/IGF-1 should be tested
remains the object of experimental and clinical research.
6. Conclusions
NAFLD designates the complex array of metabolic, histological, and extra-hepatic consequences,
which result from the intra-hepatic deposition of ectopic fat. As a reflection of our incomplete
understanding of its pathogenesis, our capacity to treat NAFLD lags far behind our ever-increasing
understanding of the global epidemiological, clinical, and economic burden of disease.
Given that they are well-characterized forms of secondary NAFLD, PCOS, hypothyroidism,
hypogonadism, and GHD were extensively discussed here with specific reference to their
epidemiological hallmarks, pathophysiological features, and principles of diagnosis and management.
The findings that both androgen excess (such as observed in certain phenotypes of PCOS)
and androgen deficiency (such as seen in male hypogonadism) are associated with an increased
risk of NAFLD strongly suggest that the contribution of sex hormones to the development and
progression of NAFLD is far from simple. It was logically postulated that metabolic health is
associated with a specific androgen/estrogen/androgen ratio in either sex, and changes of this ratio will
induce metabolic derangements and NAFLD [168]. In male rodents, androgens, by regulating genes
involved in hepatic lipogenesis and glucose metabolism, protect from NAFLD and insulin resistance
through a dual mechanism: via androgen receptor signaling and via estrogen receptor signaling
(following aromatization of testosterone to estradiol) [169]. In contrast, in female rodents, it is estradiol
which protects from NAFLD, whereas androgens promote both NAFLD and dysglycemia [169]. These
notions receive credibility by the acknowledged activity of sex hormones and their receptors in
regulating liver energy homeostasis and body fat distribution [110]. Stated otherwise, androgen excess
in women and androgen deficiency in men both manifest with a shared dysmetabolic phenotype,
featuring abdominal obesity, type 2 diabetes, insulin resistance, NAFLD, and excess cardiovascular
risk (Table 3).
We are not aware of any comparative studies specifically addressing similarities and differences
between the natural course of NAFLD secondary to endocrine disorders as opposed to the course
of primary NAFLD. That said, we point out that the development of hepatocellular carcinoma in
individuals with hypothyroidism was reported (reviewed in Reference [19]). This implies that this
specific form of NAFLD has the potential to run the complete course of NAFLD from uncomplicated
simple steatosis to end-stage liver disease. In contrast, while the presence of advanced fibrosis was
consistently reported in patients with PCOS [28], to our knowledge, there are currently no published
reports of well-documented cases of hepatocellular carcinoma occurring in patients with PCOS. As far
as hypogonadism is concerned, Klinefelter’s syndrome is exceptionally associated with primary biliary
cholangitis rather than with NASH–cirrhosis [170,171]. Turner syndrome is rarely associated with
NASH–cirrhosis [172]. However, we are not aware of any cases of NAFLD-related hepatocellular
carcinoma occurring in hypogonadic patients.
Collectively, the above-discussed forms of NAFLD secondary to some common endocrine
derangements represent a naturally occurring disease model of NAFLD in humans. Therefore,
a better understanding of their features promises to disclose novel clinical associations and innovative
therapeutic approaches, which may potentially be exploited for use also in selected cases of primary
NAFLD. However, further basic and clinical research is certainly needed to achieve this ambitious aim.
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Abbreviations
ACTH adrenocorticotropic hormone
AGHD adult growth hormone deficiency
AMPK AMP-activated protein kinase
apo apolipoprotein
BAAT index body mass index, age, ALT, and triglyceride
BMI body mass index
CCL3 C–C motif chemokine ligand 3
CI confidence interval
ERK extracellular signal-regulated kinase
FT4 free thyroxine
GH growth hormone
GHD growth hormone deficiency
GHRH GH-releasing hormone
GHRLD liver-specific deletion of GH receptor
HDL high-density lipoprotein
hypertension arterial hypertension
IGF-1 insulin-like growth factor-1
JAK-2 Janus kinase 2
JAK2L liver-specific JAK2-deficient
JNK c-Jun N-terminal kinase
LDL low-density lipoprotein
LH luteinizing hormone
MAPK mitogen-activated protein kinase
MKK3 MAP kinase-activated protein kinase-3
MKK-4 MAP kinase-activated protein kinase-4
MRI magnetic resonance imaging
MRS magnetic resonance spectroscopy
NAFLD nonalcoholic fatty liver disease
NASH nonalcoholic steatohepatitis
OR odds ratio
PCOS polycystic ovary syndrome
PI3K phosphoinositide 3-kinase
PKC protein kinase C
PPARα peroxisome proliferator-activated receptor-α
ROS reactive oxygen species
SREBP-1c sterol regulatory element-binding
STAT-5 signal transducer and activator of transcription 5
TNF-α tumor necrosis factor-α
TSH thyroid-stimulating hormone
VLDL very low-density lipoprotein
References
1. Petäjä, E.M.; Yki-Järvinen, H. Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with
Acquired and Genetic NAFLD-A Systematic Review. Int. J. Mol. Sci. 2016, 17, 633.
2. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease
(NAFLD): Updates and future directions. Dig. Liver Dis. 2017, 49, 471–483. [CrossRef] [PubMed]
3. Younossi, Z.; Tacke, F.; Arrese, M.; Sharma, B.C.; Mostafa, I.; Bugianesi, E.; Wong, V.W.; Yilmaz, Y.; George, J.;
Fan, J.; et al. Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis.
Hepatology 2019, 69, 2672–2682. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 26 of 34
4. Fazel, Y.; Koenig, A.B.; Sayiner, M.; Goodman, Z.D.; Younossi, Z.M. Epidemiology and natural history of
non-alcoholic fatty liver disease. Metabolism 2016, 65, 1017–1025. [CrossRef]
5. Vilar-Gomez, E.; Calzadilla-Bertot, L.; Wai-Sun Wong, V.; Castellanos, M.; Aller-de la Fuente, R.; Metwally, M.;
Eslam, M.; Gonzalez-Fabian, L.; Alvarez-Quiñones Sanz, M.; Conde-Martin, A.F.; et al. Fibrosis Severity as
a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease:
A Multi-National Cohort Study. Gastroenterology 2018, 155, 443–457. [CrossRef] [PubMed]
6. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes
(EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice
Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 2016, 64, 1388–1402. [CrossRef]
[PubMed]
7. Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.;
Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the
American Association for the Study of Liver Diseases. Hepatology 2018, 67, 328–357. [CrossRef] [PubMed]
8. Lonardo, A.; Ballestri, S.; Marchesini, G.; Angulo, P.; Loria, P. Nonalcoholic fatty liver disease: a precursor of
the metabolic syndrome. Dig. Liver Dis. 2015, 47, 181–190. [CrossRef] [PubMed]
9. Iwen, K.A.; Oelkrug, R.; Kalscheuer, H.; Brabant, G. Metabolic Syndrome in Thyroid Disease. Front. Horm.
Res. 2018, 49, 48–66.
10. Rastrelli, G.; Filippi, S.; Sforza, A.; Maggi, M.; Corona, G. Metabolic Syndrome in Male Hypogonadism.
Front. Horm. Res. 2018, 49, 131–155.
11. Dwyer, A.A.; Quinton, R. The Metabolic Syndrome in Central Hypogonadotrophic Hypogonadism.
Front. Horm. Res. 2018, 49, 156–169. [PubMed]
12. Pasquali, R. Metabolic Syndrome in Polycystic Ovary Syndrome. Front. Horm. Res. 2018, 49, 114–130.
[PubMed]
13. Miljic´, D.; Popovic, V. Metabolic Syndrome in Hypopituitarism. Front. Horm. Res. 2018, 49, 1–19. [PubMed]
14. Lonardo, A.; Nascimbeni, F.; Mantovani, A.; Targher, G. Hypertension, diabetes, atherosclerosis and NASH:
Cause or consequence? J. Hepatol. 2018, 68, 335–352. [CrossRef] [PubMed]
15. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221–1231. [CrossRef] [PubMed]
16. Lonardo, A.; Carani, C.; Carulli, N.; Loria, P. ‘Endocrine NAFLD’ a hormonocentric perspective of nonalcoholic
fatty liver disease pathogenesis. J. Hepatol. 2006, 44, 1196–1207. [CrossRef] [PubMed]
17. Loria, P.; Carulli, L.; Bertolotti, M.; Lonardo, A. Endocrine and liver interaction: the role of endocrine
pathways in NASH. Nat. Rev. Gastroenterol. Hepatol. 2009, 6, 236–247. [CrossRef] [PubMed]
18. Manka, P.; Bechmann, L.; Best, J.; Sydor, S.; Claridge, L.C.; Coombes, J.D.; Canbay, A.; Moeller, L.; Gerken, G.;
Wedemeyer, H.; et al. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High
Risk for Nonalcoholic Steatohepatitis. Dig. Dis. Sci. 2019. [CrossRef]
19. Lonardo, A.; Ballestri, S.; Mantovani, A.; Nascimbeni, F.; Lugari, S.; Targher, G. Pathogenesis of
hypothyroidism-induced NAFLD: Evidence for a distinct disease entity? Dig. Liver Dis. 2019, 5, 462–470.
[CrossRef]
20. McCartney, C.R.; Marshall, J.C. Clinical practice. Polycystic ovary syndrome. N. Engl. J. Med. 2016, 375,
54–64. [CrossRef]
21. Anagnostis, P.; Tarlatzis, B.C.; Kauffman, R.P. Polycystic ovarian syndrome (PCOS): long-term metabolic
consequences. Metabolism 2018, 86, 33–43. [CrossRef]
22. Targher, G.; Zoppini, G.; Bonora, E.; Moghetti, P. Hemostatic and fibrinolytic abnormalities in polycystic
ovary syndrome. Semin. Thromb. Hemost. 2014, 40, 600–618.
23. Stein, I.F.; Leventhal, M.L. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol.
1935, 29, 181–191. [CrossRef]
24. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on
diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod.
2004, 19, 41–47. [CrossRef]
25. Sirmans, S.M.; Pate, K.A. Epidemiology, diagnosis, and management of polycystic ovary syndrome.
Clin. Epidemiol. 2014, 6, 1–13. [CrossRef] [PubMed]
26. Yildiz, B.O.; Bozdag, G.; Yapici, Z.; Esinler, I.; Yarali, H. Prevalence, phenotype and cardiometabolic risk of
polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 2012, 27, 3067–3073. [CrossRef]
[PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 27 of 34
27. Targher, G.; Rossini, M.; Lonardo, A. Evidence that non-alcoholic fatty liver disease and polycystic ovary
syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine 2016, 51,
211–221. [CrossRef] [PubMed]
28. Setji, T.L.; Holland, N.D.; Sanders, L.L.; Pereira, K.C.; Diehl, A.M.; Brown, A.J. Nonalcoholic steatohepatitis
and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J. Clin. Endocrinol.
Metab. 2006, 91, 1741–1747. [CrossRef] [PubMed]
29. Brzozowska, M.M.; Ostapowicz, G.; Weltman, M.D. An association between non-alcoholic fatty liver disease
and polycystic ovarian syndrome. J. Gastroenterol. Hepatol. 2009, 24, 243–247. [CrossRef]
30. Hossain, N.; Stepanova, M.; Afendy, A.; Nader, F.; Younossi, Y.; Rafiq, N.; Goodman, Z.; Younossi, Z.M.
Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS). Scand. J.
Gastroenterol. 2011, 46, 479–484. [CrossRef]
31. Wu, J.; Yao, X.Y.; Shi, R.X.; Liu, S.F.; Wang, X.Y. A potential link between polycystic ovary syndrome and
non-alcoholic fatty liver disease: an update meta-analysis. Reprod. Health 2018, 15, 77. [CrossRef] [PubMed]
32. Jones, H.; Sprung, V.S.; Pugh, C.J.; Daousi, C.; Irwin, A.; Aziz, N.; Adams, V.L.; Thomas, E.L.; Bell, J.D.;
Kemp, G.J.; et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk
of hepatic steatosis compared to non-hyperandrogenic PCOS phenotypes and healthy controls, independent
of obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2012, 97, 3709–3716. [CrossRef] [PubMed]
33. Kim, J.J.; Kim, D.; Yim, J.Y.; Kang, J.H.; Han, K.H.; Kim, S.M.; Hwang, K.R.; Ku, S.Y.; Suh, C.S.; Kim, S.H.;
et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty
liver disease. Aliment Pharmacol. Ther. 2017, 45, 1403–1412. [CrossRef] [PubMed]
34. Kumarendran, B.; O’Reilly, M.W.; Manolopoulos, K.N.; Toulis, K.A.; Gokhale, K.M.; Sitch, A.J.;
Wijeyaratne, C.N.; Coomarasamy, A.; Arlt, W.; Nirantharakumar, K. Polycystic ovary syndrome, androgen
excess, and the risk of nonalcoholic fatty liver disease in women: a longitudinal study based on a United
Kingdom primary care database. PLoS Med. 2018, 15, e1002542. [CrossRef] [PubMed]
35. Vassilatou, E.; Lafoyianni, S.; Vryonidou, A.; Ioannidis, D.; Kosma, L.; Katsoulis, K.; Papavassiliou, E.;
Tzavara, I. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women
with polycystic ovary syndrome. Hum. Reprod. 2010, 25, 212–220. [CrossRef] [PubMed]
36. Cussons, A.J.; Watts, G.F.; Mori, T.A.; Stuckey, B.G. Omega-3 fatty acid supplementation decreases liver fat
content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance
spectroscopy. J. Clin. Endocrinol. Metab. 2009, 94, 3842–3848. [CrossRef]
37. Dawson, A.J.; Sathyapalan, T.; Smithson, J.A.; Vince, R.V.; Coady, A.M.; Ajjan, R.; Kilpatrick, E.S.; Atkin, S.L.
A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without
coexisting nonalcoholic fatty liver disease. Clin. Endocrinol. 2014, 80, 843–849. [CrossRef] [PubMed]
38. Byrne, C.D.; Patel, J.; Scorletti, E.; Targher, G. Tests for diagnosing and monitoring non-alcoholic fatty liver
disease in adults. BMJ 2018, 362, k2734. [CrossRef]
39. Baptiste, C.G.; Battista, M.C.; Trottier, A.; Baillargeon, J.P. Insulin and hyperandrogenism in women with
polycystic ovary syndrome. J. Steroid Biochem. Mol. Biol. 2010, 122, 42–52. [CrossRef]
40. Munir, I.; Yen, H.W.; Geller, D.H.; Torbati, D.; Bierden, R.M.; Weitsman, S.R.; Agarwal, S.K.; Magoffin, D.A.
Insulin augmentation of 17alpha-hydroxylase activity is mediated by phosphatidyl inositol 3- kinase but
not extracellular signal-regulated kinase-1/2 in human ovarian theca cells. Endocrinology 2004, 145, 175–183.
[CrossRef]
41. Wickenheisser, J.K.; Nelson-DeGrave, V.L.; McAllister, J.M. Human ovarian theca cells in culture. Trends
Endocrinol. Metab. 2006, 17, 65–71. [CrossRef] [PubMed]
42. Abbott, D.H.; Dumesic, D.A.; Levine, J.E. Hyperandrogenic origins of polycystic ovary
syndrome—Implications for pathophysiology and therapy. Expert Rev. Endocrinol. Metab. 2019, 14,
131–143. [CrossRef] [PubMed]
43. Schiffer, L.; Kempegowda, P.; Arlt, W.; O’Reilly, M.W. MECHANISMS IN ENDOCRINOLOGY: The sexually
dimorphic role of androgens in human metabolic disease. Eur. J. Endocrinol. 2017, 177, R125–R143. [CrossRef]
[PubMed]
44. Du, Q.; Wang, Y.J.; Yang, S.; Wu, B.; Han, P.; Zhao, Y.Y. A systematic review and meta-analysis of randomized
controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Curr. Med. Res. Opin. 2012, 28, 723–730. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 28 of 34
45. Tzotzas, T.; Karras, S.N.; Katsiki, N. Glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment
of obese women with polycystic ovary syndrome. Curr. Vasc. Pharmacol. 2017, 15, 218–229. [CrossRef]
[PubMed]
46. Frøssing, S.; Nylander, M.; Chabanova, E.; Frystyk, J.; Holst, J.J.; Kistorp, C.; Skouby, S.O.; Faber, J. Effect of
liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes. Metab.
2018, 20, 215–218. [CrossRef] [PubMed]
47. Chaker, L.; Bianco, A.C.; Jonklaas, J.; Peeters, R.P. Hypothyroidism. Lancet 2017, 390, 1550–1562. [CrossRef]
48. Sinha, R.A.; Singh, B.K.; Yen, P.M. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism.
Trends Endocrinol. Metab. 2014, 25, 538–545. [CrossRef] [PubMed]
49. Sinha, R.A.; Singh, B.K.; Yen, P.M. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat. Rev.
Endocrinol. 2018, 14, 259–269. [CrossRef]
50. Kar, K.; Sinha, S. Variations of adipokines and insulin resistance in primary hypothyroidism. J. Clin. Diagn
Res. 2017, 11, BC07–BC09. [CrossRef] [PubMed]
51. Leonhardt, U.; Ritzel, U.; Schäfer, G.; Becker, W.; Ramadori, G. Serum leptin levels in hypo and
hyperthyroidism. J. Endocrinol. 1998, 157, 75–79. [CrossRef]
52. Mantovani, A.; Grani, G. Thyroid Dysfunction and Nonalcoholic Fatty Liver Disease: We Need New Larger
and Well-Designed Longitudinal Studies. Dig. Dis. Sci. 2018, 63, 1970–1976. [CrossRef]
53. Liangpunsakul, S.; Chalasani, N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis? J. Clin.
Gastroenterol. 2003, 37, 340–343. [CrossRef] [PubMed]
54. Xu, C.; Xu, L.; Yu, C.; Miao, M.; Li, Y. Association between thyroid function and nonalcoholic fatty liver
disease in euthyroid elderly Chinese. Clin. Endocrinol. (Oxf.) 2011, 75, 240–246. [CrossRef] [PubMed]
55. Zhang, J.; Sun, H.; Chen, L.; Zheng, J.; Hu, X.; Wang, S.; Chen, T. Relationship between serum TSH level
with obesity and NAFLD in euthyroid subjects. J. Huazhong Univ. Sci. Technol. Med. Sci. 2012, 32, 47–52.
[CrossRef] [PubMed]
56. Ittermann, T.; Haring, R.; Wallaschofski, H.; Baumeister, S.E.; Nauck, M.; Dörr, M.; Lerch, M.M.; Meyer zu
Schwabedissen, H.E.; Rosskopf, D.; Völzke, H. Inverse association between serum free thyroxine levels and
hepatic steatosis: Results from the Study of Health in Pomerania. Thyroid 2012, 22, 568–574. [CrossRef]
[PubMed]
57. Pagadala, M.R.; Zein, C.O.; Dasarathy, S.; Yerian, L.M.; Lopez, R.; McCullough, A.J. Prevalence of
hypothyroidism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 2012, 57, 528–534. [CrossRef] [PubMed]
58. Chung, G.E.; Kim, D.; Kim, W.; Yim, J.Y.; Park, M.J.; Kim, Y.J.; Yoon, J.H.; Lee, H.S. Non-alcoholic fatty liver
disease across the spectrum of hypothyroidism. J. Hepatol. 2012, 57, 150–156. [CrossRef]
59. Xu, L.; Ma, H.; Miao, M.; Li, Y. Impact of subclinical hypothyroidism on the development of non-alcoholic
fatty liver disease: A prospective case-control study. J. Hepatol. 2012, 57, 1153–1154. [CrossRef]
60. Carulli, L.; Ballestri, S.; Lonardo, A.; Lami, F.; Violi, E.; Losi, L.; Bonilauri, L.; Verrone, A.M.; Odoardi, M.R.;
Scaglioni, F.; et al. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating
hormone level and lower cholesterol levels? Intern. Emerg. Med. 2013, 8, 297–305. [CrossRef] [PubMed]
61. Eshraghian, A.; Dabbaghmanesh, M.H.; Eshraghian, H.; Fattahi, M.R.; Omrani, G.R. Nonalcoholic fatty liver
disease in a cluster of Iranian population: Thyroid status and metabolic risk factors. Arch. Iran. Med. 2013,
16, 584–589. [PubMed]
62. Posadas-Romero, C.; Jorge-Galarza, E.; Posadas-Sánchez, R.; Acuña-Valerio, J.; Juárez-Rojas, J.G.;
Kimura-Hayama, E.; Medina-Urrutia, A.; Cardoso-Saldaña, G.C. Fatty liver largely explains associations
of subclinical hypothyroidism with insulin resistance, metabolic syndrome, and subclinical coronary
atherosclerosis. Eur. J. Endocrinol. 2014, 171, 319–325. [CrossRef]
63. Tao, Y.; Gu, H.; Wu, J.; Sui, J. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid
subjects. Endocr. Res. 2015, 40, 74–78. [CrossRef]
64. Liu, G.; Zheng, X.; Guan, L.; Jiang, Z.; Lin, H.; Jiang, Q.; Zhang, N.; Zhang, Y.; Zhang, X.; Yu, C.; et al.
Free triiodothyronine levels are positively associated with non-alcoholic fatty liver disease in euthyroid
middle-aged subjects. Endocr. Res. 2015, 40, 188–193. [CrossRef] [PubMed]
65. Ding, W.J.; Wang, M.M.; Wang, G.S.; Shen, F.; Qin, J.J.; Fan, J.G. Thyroid function is associated with
non-alcoholic fatty liver disease in chronic hepatitis B-infected subjects. J. Gastroenterol. Hepatol. 2015, 30,
1753–1758. [CrossRef]
Int. J. Mol. Sci. 2019, 20, 2841 29 of 34
66. Parikh, P.; Phadke, A.; Sawant, P. Prevalence of hypothyroidism in nonalcoholic fatty liver disease in patients
attending a tertiary hospital in western India. Indian. J. Gastroenterol. 2015, 34, 169–173.
67. Ludwig, U.; Holzner, D.; Denzer, C.; Greinert, A.; Haenle, M.M.; Oeztuerk, S.; Koenig, W.; Boehm, B.O.;
Mason, R.A.; Kratzer, W.; et al. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease:
A cross-sectional study of a random population sample aged 18 to 65 years. BMC Endocr. Disord. 2015, 15, 41.
[CrossRef] [PubMed]
68. Lee, K.W.; Bang, K.B.; Rhee, E.J.; Kwon, H.J.; Lee, M.Y.; Cho, Y.K. Impact of hypothyroidism on the
development of non-alcoholic fatty liver disease: A 4-year retrospective cohort study. Clin. Mol. Hepatol.
2015, 21, 372–378. [CrossRef] [PubMed]
69. Bril, F.; Kadiyala, S.; Portillo Sanchez, P.; Sunny, N.E.; Biernacki, D.; Maximos, M.; Kalavalapalli, S.;
Lomonaco, R.; Suman, A.; Cusi, K. Plasma thyroid hormone concentration is associated with hepatic
triglyceride content in patients with type 2 diabetes. J. Investig. Med. 2016, 64, 63–68. [CrossRef] [PubMed]
70. Bano, A.; Chaker, L.; Plompen, E.P.; Hofman, A.; Dehghan, A.; Franco, O.H.; Janssen, H.L.; Darwish Murad, S.;
Peeters, R.P. Thyroid function and the risk of nonalcoholic fatty liver disease: The Rotterdam study. J. Clin.
Endocrinol. Metab. 2016, 101, 3204–3211. [CrossRef] [PubMed]
71. Gökmen, F.Y.; Ahbab, S.; Ataog˘lu, H.E.; Türker, B.Ç.; Çetin, F.; Türker, F.; Mamaç, R.Y.; Yenigün, M.
FT3/FT4 ratio predicts non-alcoholic fatty liver disease independent of metabolic parameters in patients with
euthyroidism and hypothyroidism. Clinics (Sao Paulo) 2016, 71, 221–225. [CrossRef]
72. van den Berg, E.H.; van Tienhoven-Wind, L.J.M.; Amini, M.; Schreuder, T.C.; Faber, K.N.; Blokzijl, H.;
Dullaart, R.P. Higher free triiodothyronine is associated with non-alcoholic fatty liver disease in euthyroid
subjects: The Lifelines Cohort Study. Metabolism 2017, 67, 62–71. [CrossRef] [PubMed]
73. Lingad-Sayas, R.C.; Montano, C.N.; Isidro, M.J.C. Prevalence of elevated TSH and its association with
dyslipidemia and NAFLD among Filipino adult executive check-up patients in a tertiary hospital. Philipp. J.
Intern. Med. 2017, 55, 1–8.
74. Mohanty, R.; Das, S.N.; Jena, A.K.; Behera, S.; Sahu, N.C.; Mohanty, B.; Suna, S.P.; Thatoi, P.K. Prevalence of
non-alcoholic fatty liver disease in hypothyroidism in a tertiary care hospital in eastern India. J. Evol. Med.
Dent. Sci. 2017, 6, 5589–5593. [CrossRef]
75. Kim, D.; Kim, W.; Joo, S.K.; Bae, J.M.; Kim, J.H.; Ahmed, A. Subclinical hypothyroidism and low-normal
thyroid function are associated with nonalcoholic steatohepatitis and fibrosis. Clin. Gastroenterol. Hepatol.
2018, 16, 123–131. [CrossRef] [PubMed]
76. Lee, J.; Ha, J.; Jo, K.; Lim, D.J.; Lee, J.M.; Chang, S.A.; Kang, M.I.; Cha, B.Y.; Kim, M.H. Male-specific
association between subclinical hypothyroidism and the risk of non-alcoholic fatty liver disease estimated by
hepatic steatosis index: Korea National Health and Nutrition Examination Survey 2013 to 2015. Sci. Rep.
2018, 8, 15145. [CrossRef] [PubMed]
77. Jaruvongvanich, V.; Sanguankeo, A.; Upala, S. Nonalcoholic fatty liver disease is not associated with thyroid
hormone levels and hypothyroidism: A systematic review and meta-analysis. Eur. Thyroid J. 2017, 6, 208–215.
[CrossRef] [PubMed]
78. He, W.; An, X.; Li, L.; Shao, X.; Li, Q.; Yao, Q.; Zhang, J.A. Relationship between hypothyroidism and
non-alcoholic fatty liver disease: A systematic review and meta-analysis. Front. Endocrinol. 2017, 8, 335.
[CrossRef] [PubMed]
79. Mantovani, A.; Nascimbeni, F.; Lonardo, A.; Zoppini, G.; Bonora, E.; Mantzoros, C.S.; Targher, G. Association
Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and
Meta-Analysis. Thyroid 2018, 28, 1270–1284. [CrossRef]
80. Guo, Z.; Li, M.; Han, B.; Qi, X. Association of non-alcoholic fatty liver disease with thyroid function:
A systematic review and meta-analysis. Dig. Liver Dis. 2018, 50, 1153–1162. [CrossRef] [PubMed]
81. Lugari, S.; Mantovani, A.; Nascimbeni, F.; Lonardo, A. Hypothyroidism and nonalcoholic fatty liver disease-a
chance association? Horm. Mol. Biol. Clin. Investig. 2018. [CrossRef] [PubMed]
82. Byrne, C.D.; Targher, G. NAFLD: a multisystem disease. J. Hepatol. 2015, 62, S47–S64. [CrossRef] [PubMed]
83. Yan, F.; Wang, Q.; Lu, M.; Chen, W.; Song, Y.; Jing, F.; Guan, Y.; Wang, L.; Lin, Y.; Bo, T.; et al. Thyrotropin
increases hepatic triglyceride content through upregulation of SREBP-1c activity. J. Hepatol. 2014, 61,
1358–1364. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 30 of 34
84. Bril, F.; Kadiyala, S.; Cusi, K. Re: “Association Between Primary Hypothyroidism and Nonalcoholic Fatty
Liver Disease: A Systematic Review and Meta-Analysis” by Mantovani et al. (Thyroid 2018;28:1270-1284).
Thyroid 2019, 29, 452. [CrossRef] [PubMed]
85. Liu, L.; Yu, Y.; Zhao, M.; Zheng, D.; Zhang, X.; Guan, Q.; Xu, C.; Gao, L.; Zhao, J.; Zhang, H. Benefits of
levothyroxine replacement therapy on nonalcoholic fatty liver disease in subclinical hypothyroidism patients.
Int. J. Endocrinol. 2017, 2017, 5753039. [CrossRef] [PubMed]
86. Bruinstroop, E.; Dalan, R.; Yang, C.; Bee, Y.M.; Chandran, K.; Cho, L.W.; Soh, S.B.; Teo, E.K.; Toh, S.A.;
Leow, M.K.S.; et al. Low dose levothyroxine reduces intrahepatic lipid content in patients with type 2
diabetes mellitus and NAFLD. J. Clin. Endocrinol. Metab. 2018, 103, 2698–2706. [CrossRef] [PubMed]
87. Mintziori, G.; Poulakos, P.; Tsametis, C.; Goulis, D.G. Hypogonadism and non-alcoholic fatty liver disease.
Minerva Endocrinol. 2017, 42, 145–150. [PubMed]
88. Haider, A.; Gooren, L.J.; Padungtod, P.; Saad, F. Improvement of the metabolic syndrome and of non-alcoholic
liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate.
Exp. Clin. Endocrinol. Diabetes 2010, 118, 167–171. [CrossRef] [PubMed]
89. Seo, N.K.; Koo, H.S.; Haam, J.H.; Kim, H.Y.; Kim, M.J.; Park, K.C.; Park, K.S.; Kim, Y.S. Prediction of prevalent
but not incident non-alcoholic fatty liver disease by levels of serum testosterone. J. Gastroenterol. Hepatol.
2015, 30, 1211–1216. [CrossRef] [PubMed]
90. Wang, W.B.; She, F.; Xie, L.F.; Yan, W.H.; Ouyang, J.Z.; Wang, B.A.; Ma, H.Y.; Zang, L.; Mu, Y.M. Evaluation of
Basal Serum Adrenocorticotropic Hormone and Cortisol Levels and Their Relationship with Nonalcoholic
Fatty Liver Disease in Male Patients with Idiopathic Hypogonadotropic Hypogonadism. Chin. Med. J. 2016,
129, 1147–1153. [CrossRef]
91. Barbonetti, A.; Caterina Vassallo, M.R.; Cotugno, M.; Felzani, G.; Francavilla, S.; Francavilla, F. Low
testosterone and non-alcoholic fatty liver disease: Evidence for their independent association in men with
chronic spinal cord injury. J. Spinal Cord Med. 2016, 39, 443–449. [CrossRef] [PubMed]
92. Gild, P.; Cole, A.P.; Krasnova, A.; Dickerman, B.A.; von Landenberg, N.; Sun, M.; Mucci, L.A.; Lipsitz, S.R.;
Chun, F.K.; Nguyen, P.L.; et al. Liver Disease in Men Undergoing Androgen Deprivation Therapy for
Prostate Cancer. J. Urol. 2018, 200, 573–581. [CrossRef] [PubMed]
93. Elsheikh, M.; Hodgson, H.J.; Wass, J.A.; Conway, G.S. Hormone replacement therapy may improve hepatic
function in women with Turner’s syndrome. Clin. Endocrinol. 2001, 55, 227–231. [CrossRef]
94. Bruno, S.; Maisonneuve, P.; Castellana, P.; Rotmensz, N.; Rossi, S.; Maggioni, M.; Persico, M.; Colombo, A.;
Monasterolo, F.; Casadei-Giunchi, D.; et al. Incidence and risk factors for non-alcoholic steatohepatitis:
prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005, 330, 932.
[CrossRef] [PubMed]
95. McKenzie, J.; Fisher, B.M.; Jaap, A.J.; Stanley, A.; Paterson, K.; Sattar, N. Effects of HRT on liver enzyme levels
in women with type 2 diabetes: a randomized placebo-controlled trial. Clin. Endocrinol. 2006, 65, 40–44.
[CrossRef] [PubMed]
96. Koulouri, O.; Ostberg, J.; Conway, G.S. Liver dysfunction in Turner’s syndrome: prevalence, natural history
and effect of exogenous oestrogen. Clin. Endocrinol. 2008, 69, 306–310. [CrossRef] [PubMed]
97. El-Mansoury, M.; Berntorp, K.; Bryman, I.; Hanson, C.; Innala, E.; Karlsson, A.; Landin-Wilhelmsen, K.
Elevated liver enzymes in Turner syndrome during a 5-year follow-up study. Clin. Endocrinol. 2008, 68,
485–490. [CrossRef]
98. Gutierrez-Grobe, Y.; Ponciano-Rodríguez, G.; Ramos, M.H.; Uribe, M.; Méndez-Sánchez, N. Prevalence of
non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women.
The role of estrogens. Ann. Hepatol. 2010, 9, 402–409.
99. Yang, J.D.; Abdelmalek, M.F.; Pang, H.; Guy, C.D.; Smith, A.D.; Diehl, A.M.; Suzuki, A. Gender and
menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis. Hepatology 2014, 59,
1406–1414. [CrossRef]
100. Hanew, K. Women with Turner syndrome are at high risk of lifestyle-related disease—From questionnaire
surveys by the Foundation for Growth Science in Japan. Endocr. J. 2016, 63, 449–456. [CrossRef]
101. Yang, Y.J.; Kim, K.M.; An, J.H.; Lee, D.B.; Shim, J.H.; Lim, Y.S.; Lee, H.C.; Lee, Y.S.; Ahn, J.H.; Jung, K.H.; et al.
Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients.
Breast 2016, 28, 67–72. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 31 of 34
102. Klair, J.S.; Yang, J.D.; Abdelmalek, M.F.; Guy, C.D.; Gill, R.M.; Yates, K.; Unalp-Arida, A.; Lavine, J.E.;
Clark, J.M.; Diehl, A.M.; et al. Nonalcoholic Steatohepatitis Clinical Research Network. A longer duration
of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver
disease. Hepatology 2016, 64, 85–91. [CrossRef] [PubMed]
103. Lonardo, A.; Nascimbeni, F.; Ballestri, S.; Fairweather, D.L.; Win, S.; Than, T.A.; Manal, F.; Abdelmalek, M.F.;
Suzuki, A. Sex Differences in NAFLD: State of the Art and Identification of Research Gaps. Hepatology 2019.
[CrossRef] [PubMed]
104. Matsuo, K.; Gualtieri, M.R.; Cahoon, S.S.; Jung, C.E.; Paulson, R.J.; Shoupe, D.; Muderspach, L.I.; Wakatsuki, A.;
Wright, J.D.; Roman, L.D. Surgical menopause and increased risk of nonalcoholic fatty liver disease in
endometrial cancer. Menopause 2016, 23, 189–196. [CrossRef] [PubMed]
105. Wang, Z.; Xu, M.; Hu, Z.; Shrestha, U.K. Prevalence of nonalcoholic fatty liver disease and its metabolic risk
factors in women of different ages and body mass index. Menopause 2015, 22, 667–673. [CrossRef] [PubMed]
106. Venetsanaki, V.; Polyzos, S.A. Menopause and non-alcoholic fatty liver disease: A review focusing on
therapeutic perspective. Curr. Vasc. Pharmacol. 2018. [CrossRef] [PubMed]
107. Kamada, Y.; Kiso, S.; Yoshida, Y.; Chatani, N.; Kizu, T.; Hamano, M.; Tsubakio, M.; Takemura, T.; Ezaki, H.;
Hayashi, N.; et al. Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet.
Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 301, G1031–G1043. [CrossRef] [PubMed]
108. Shen, M.; Shi, H. Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis. Int. J. Endocrinol.
2015, 2015, 294278. [CrossRef]
109. Sakr, H.F.; Hussein, A.M.; Eid, E.A.; AIKhateeb, M. Possible mechanisms underlying fatty liver in a rat model
of male hypogonadism: A protective role for testosterone. Steroids 2018, 135, 21–30. [CrossRef]
110. Maffei, L.; Murata, Y.; Rochira, V.; Tubert, G.; Aranda, C.; Vazquez, M.; Clyne, C.D.; Davis, S.; Simpson, E.R.;
Carani, C. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of
testosterone, alendronate, and estradiol treatment. J. Clin. Endocrinol. Metab. 2004, 89, 61–70. [CrossRef]
111. Maffei, L.; Rochira, V.; Zirilli, L.; Antunez, P.; Aranda, C.; Fabre, B.; Simone, M.L.; Pignatti, E.; Simpson, E.R.;
Houssami, S.; et al. A novel compound heterozygous mutation of the aromatase gene in an adult man:
reinforced evidence on the relationship between congenital oestrogen deficiency, adiposity and the metabolic
syndrome. Clin. Endocrinol. 2007, 67, 218–224. [CrossRef] [PubMed]
112. Kander, M.C. Gender difference in oxidative stress: a new look at the mechanisms for cardiovascular diseases.
J. Cell Mol. Med. 2017, 21, 1024–1032. [CrossRef] [PubMed]
113. Chukijrungroat, N. Hepatic FGF21 mediates sex differences in high-fat high-fructose diet-induced fatty liver.
Am. J. Physiol. Endocrinol. Metab. 2017, 313, E203–E212. [CrossRef] [PubMed]
114. Harada, N. Hypogonadism alters cecal and fecal microbiota in male mice. Gut Microbes 2016, 7, 533–539.
[CrossRef] [PubMed]
115. Charlton, M.; Angulo, P.; Chalasani, N.; Merriman, R.; Viker, K.; Charatcharoenwitthaya, P.; Sanderson, S.;
Gawrieh, S.; Krishnan, A.; Lindor, K. Low circulating levels of dehydroepiandrosterone in histologically
advanced nonalcoholic fatty liver disease. Hepatology 2008, 47, 484–492. [CrossRef] [PubMed]
116. Sumida, Y.; Yonei, Y.; Kanemasa, K.; Hara, T.; Inada, Y.; Sakai, K.; Imai, S.; Hibino, S.; Yamaguchi, K.;
Mitsuyoshi, H.; et al. Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance,
is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol. Res.
2010, 40, 901–910. [CrossRef]
117. Koga, M.; Saito, H.; Mukai, M.; Saibara, T.; Kasayama, S. Serum dehydroepiandrosterone sulphate levels in
patients with non-alcoholic fatty liver disease. Intern. Med. 2011, 50, 1657–1661. [CrossRef]
118. Koehler, E.; Swain, J.; Sanderson, S.; Krishnan, A.; Watt, K.; Charlton, M. Growth hormone,
dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for
advanced fibrosis in obese patients. Liver Int. 2012, 32, 279–286. [CrossRef]
119. Tokushige, K.; Hashimoto, E.; Kodama, K.; Tobari, M.; Matsushita, N.; Kogiso, T.; Taniai, M.; Torii, N.;
Shiratori, K.; Nishizaki, Y.; et al. Serum metabolomic profile and potential biomarkers for severity of fibrosis
in nonalcoholic fatty liver disease. J. Gastroenterol. 2013, 48, 1392–1400. [CrossRef]
120. Zhou, J.H.; Cai, J.J.; She, Z.G.; Li, H.L. Noninvasive evaluation of nonalcoholic fatty liver disease: Current
evidence and practice. World J. Gastroenterol. 2019, 25, 1307–1326. [CrossRef]
121. Nascimbeni, F.; Pais, R.; Bellentani, S.; Day, C.P.; Ratziu, V.; Loria, P.; Lonardo, A. From NAFLD in clinical
practice to answers from guidelines. J. Hepatol. 2013, 59, 859–871. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 32 of 34
122. Nascimbeni, F.; Ballestri, S.; Machado, M.V.; Mantovani, A.; Cortez-Pinto, H.; Targher, G.; Lonardo, A.
Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert
Rev. Gastroenterol. Hepatol. 2018, 12, 351–367. [CrossRef] [PubMed]
123. Khera, M.; Broderick, G.A.; Carson, C.C.; Dobs, A.S.; Faraday, M.M.; Goldstein, I.; Hakim, L.S.; Hellstrom, W.J.;
Kacker, R.; Köhler, T.S.; et al. Adult-Onset Hypogonadism. Mayo Clin. Proc. 2016, 91, 908–926. [CrossRef]
124. Russell, N.; Grossmann, M. MECHANISMS IN ENDOCRINOLOGY: Estradiol as a male hormone. Eur. J.
Endocrinol. 2019. [CrossRef] [PubMed]
125. Sigalos, J.T.; Pastuszak, A.W.; Khera, M. Hypogonadism: Therapeutic Risks, Benefits, and Outcomes. Med.
Clin. N. Am. 2018, 102, 361–372. [CrossRef] [PubMed]
126. Klein, K.O.; Rosenfield, R.L.; Santen, R.J.; Gawlik, A.M.; Backeljauw, P.F.; Gravholt, C.H.; Sas, T.C.J.;
Mauras, N. Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations.
J. Clin. Endocrinol. Metab. 2018, 103, 1790–1803. [CrossRef]
127. Ballestri, S.; Mantovani, A.; Nascimbeni, F.; Lugari, S.; Lonardo, A. Extra-hepatic manifestations and
complications of NAFLD. Future Med. Chem.. (In Press).
128. Takahashi, Y. The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver. Int. J. Mol. Sci.
2017, 18, 1447. [CrossRef] [PubMed]
129. Vijayakumar, A.; Novosyadlyy, R.; Wu, Y.; Yakar, S.; LeRoith, D. Biological effects of growth hormone on
carbohydrate and lipid metabolism. Growth Horm. IGF Res. 2010, 20, 1–7. [CrossRef] [PubMed]
130. Kim, S.H.; Park, M.J. Effects of growth hormone on glucose metabolism and insulin resistance in human.
Ann. Pediatr. Endocrinol. Metab. 2017, 22, 145–152. [CrossRef]
131. Le Roith, D.; Bondy, C.; Yakar, S.; Liu, J.L.; Butler, A. The somatomedin hypothesis: 2001. Endocr. Rev. 2001,
22, 53–74. [CrossRef] [PubMed]
132. Savage, M.O. Insulin-like growth factors, nutrition and growth. World Rev. Nutr. Diet. 2013, 106, 52–59.
[PubMed]
133. Thomas, J.D.; Monson, J.P. Adult GH deficiency throughout lifetime. Eur. J. Endocrinol. 2009, 1, S97–S106.
[CrossRef] [PubMed]
134. Ichikawa, T.; Nakao, K.; Hamasaki, K.; Furukawa, R.; Tsuruta, S.; Ueda, Y.; Taura, N.; Shibata, H.;
Fujimoto, M.; Toriyama, K.; et al. Role of growth hormone, insulin-like growth factor 1 and insulin-like
growth factor-binding protein 3 in development of non-alcoholic fatty liver disease. Hepatol. Int. 2007, 1,
287–294. [CrossRef]
135. Xu, L.; Xu, C.; Yu, C.; Miao, M.; Zhang, X.; Zhu, Z.; Ding, X.; Li, Y. Association between serum growth
hormone levels and nonalcoholic fatty liver disease: a cross-sectional study. PLoS ONE 2012, 7, e44136.
[CrossRef]
136. Lonardo, A.; Loria, P.; Leonardi, F.; Ganazzi, D.; Carulli, N. Growth hormone plasma levels in nonalcoholic
fatty liver disease. Am. J. Gastroenterol. 2002, 97, 1071–1072. [CrossRef] [PubMed]
137. Arturi, F.; Succurro, E.; Procopio, C.; Pedace, E.; Mannino, G.C.; Lugarà, M.; Procopio, T.; Andreozzi, F.;
Sciacqua, A.; Hribal, M.L.; et al. Nonalcoholic fatty liver disease is associated with low circulating levels of
insulin-like growth factor-I. J. Clin. Endocrinol. Metab. 2011, 96, E1640–E1644. [CrossRef]
138. Liang, S.; Yu, Z.; Song, X.; Wang, Y.; Li, M.; Xue, J. Reduced Growth Hormone Secretion is Associated with
Nonalcoholic Fatty Liver Disease in Obese Children. Horm. Metab. Res. 2018, 50, 250–256. [CrossRef]
139. Sumida, Y.; Yonei, Y.; Tanaka, S.; Mori, K.; Kanemasa, K.; Imai, S.; Taketani, H.; Hara, T.; Seko, Y.; Ishiba, H.;
et al. Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological
severity of non-alcoholic fatty liver disease. Hepatol. Res. 2015, 45, 771–781. [CrossRef]
140. Dichtel, L.E.; Corey, K.E.; Misdraji, J.; Bredella, M.A.; Schorr, M.; Osganian, S.A.; Young, B.J.; Sung, J.C.;
Miller, K.K. The association between IGF-1 levels and the histological severity of Nonalcoholic Fatty Liver
Disease. Clin. Transl. Gastroenterol. 2017, 8, e217. [CrossRef]
141. Chishima, S.; Kogiso, T.; Matsushita, N.; Hashimoto, E.; Tokushige, K. The Relationship between the Growth
Hormone/Insulin-like Growth Factor System and the Histological Features of Nonalcoholic Fatty Liver
Disease. Intern. Med. 2017, 56, 473–480. [CrossRef] [PubMed]
142. Rufinatscha, K.; Ress, C.; Folie, S.; Haas, S.; Salzmann, K.; Moser, P.; Dobner, J.; Weiss, G.; Iruzubieta, P.;
Arias-Loste, M.T.; et al. Metabolic effects of reduced growth hormone action in fatty liver disease. Hepatol.
Int. 2018, 12, 474–481. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 33 of 34
143. Adams, L.A.; Feldstein, A.; Lindor, K.D.; Angulo, P. Nonalcoholic fatty liver disease among patients with
hypothalamic and pituitary dysfunction. Hepatology 2004, 39, 909–914. [CrossRef] [PubMed]
144. Nishizawa, H.; Iguchi, G.; Murawaki, A.; Fukuoka, H.; Hayashi, Y.; Kaji, H.; Yamamoto, M.; Suda, K.;
Takahashi, M.; Seo, Y.; et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH
deficiency and the impact of GH replacement therapy. Eur. J. Endocrinol. 2012, 167, 67–74. [CrossRef]
[PubMed]
145. Ichikawa, T.; Hamasaki, K.; Ishikawa, H.; Ejima, E.; Eguchi, K.; Nakao, K. Non-alcoholic steatohepatitis
and hepatic steatosis in patients with adult onset growth hormone deficiency. Gut 2003, 52, 914. [CrossRef]
[PubMed]
146. Hong, J.W.; Kim, J.Y.; Kim, Y.E.; Lee, E.J. Metabolic parameters and nonalcoholic fatty liver disease in
hypopituitary men. Horm. Metab. Res. 2011, 43, 48–54. [CrossRef] [PubMed]
147. Gardner, C.J.; Irwin, A.J.; Daousi, C.; McFarlane, I.A.; Joseph, F.; Bell, J.D.; Thomas, E.L.; Adams, V.L.;
Kemp, G.J.; Cuthbertson, D.J. Hepatic steatosis, GH deficiency and the effects of GH replacement: a Liverpool
magnetic resonance spectroscopy study. Eur. J. Endocrinol. 2012, 166, 993–1002. [CrossRef] [PubMed]
148. Meienberg, F.; Yee, M.; Johnston, D.; Cox, J.; Robinson, S.; Bell, J.D.; Thomas, E.L.; Taylor-Robinson, S.D.;
Godsland, I. Liver fat in adults with GH deficiency: comparison to matched controls and the effect of GH
replacement. Clin. Endocrinol. 2016, 85, 76–84. [CrossRef]
149. Gilliland, T.; Dufour, S.; Shulman, G.I.; Petersen, K.F.; Emre, S.H. Resolution of non-alcoholic steatohepatitis
after growth hormone replacement in a pediatric liver transplant patient with panhypopituitarism.
Pediatr. Transplant. 2016, 20, 1157–1163. [CrossRef]
150. de la Garza, R.G.; Morales-Garza, L.A.; Martin-Estal, I.; Castilla-Cortazar, I. Insulin-Like Growth Factor-1
Deficiency and Cirrhosis Establishment. J. Clin. Med. Res. 2017, 9, 233–247. [CrossRef]
151. Adamek, A.; Kasprzak, A. Insulin-Like Growth Factor (IGF) System in Liver Diseases. Int. J. Mol. Sci. 2018,
19, 1308. [CrossRef] [PubMed]
152. Fan, Y.; Fang, X.; Tajima, A.; Geng, X.; Ranganathan, S.; Dong, H.; Trucco, M.; Sperling, M.A. Evolution of
hepatic steatosis to fibrosis and adenoma formation in liver-specific growth hormone receptor knockout
mice. Front. Endocrinol. 2014, 5, 218. [CrossRef] [PubMed]
153. Cordoba-Chacon, J.; Majumdar, N.; List, E.O.; Diaz-Ruiz, A.; Frank, S.J.; Manzano, A.; Bartrons, R.;
Puchowicz, M.; Kopchick, J.J.; Kineman, R.D. Growth Hormone Inhibits Hepatic De Novo Lipogenesis in
Adult Mice. Diabetes 2015, 64, 3093–3103. [CrossRef] [PubMed]
154. Sos, B.C.; Harris, C.; Nordstrom, S.M.; Tran, J.L.; Balázs, M.; Caplazi, P.; Febbraio, M.; Applegate, M.A.;
Wagner, K.U.; Weiss, E.J. Abrogation of growth hormone secretion rescues fatty liver in mice with
hepatocyte-specific deletion of JAK2. J. Clin. Invest. 2011, 121, 1412–1423. [CrossRef] [PubMed]
155. Barclay, J.L.; Nelson, C.N.; Ishikawa, M.; Murray, L.A.; Kerr, L.M.; McPhee, T.R.; Powell, E.E.; Waters, M.J.
GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism. Endocrinology 2011, 152,
181–192. [CrossRef]
156. Nishizawa, H.; Takahashi, M.; Fukuoka, H.; Iguchi, G.; Kitazawa, R.; Takahashi, Y. GH-independent IGF-1
action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model.
Biochem. Biophys. Res. Commun. 2012, 423, 295–300. [CrossRef] [PubMed]
157. Puche, J.E.; García-Fernández, M.; Muntané, J.; Rioja, J.; González-Barón, S.; Castilla Cortazar, I. Low doses of
insulin-like growth factor-I induce mitochondrial protection in aging rats. Endocrinology 2008, 149, 2620–2627.
[CrossRef] [PubMed]
158. Karamitri, A.; Jockers, R. Melatonin in type 2 diabetes mellitus and obesity. Nat. Rev. Endocrinol. 2019, 15,
105–125. [CrossRef]
159. Zhou, H.; Du, W.; Li, Y.; Shi, C.; Hu, N.; Ma, S.; Wang, W.; Ren, J. Effects of melatonin on fatty liver disease:
The role of NR4A1/DNA-PKcs/p53 pathway, mitochondrial fission, and mitophagy. J. Pineal Res. 2018, 64,
e12450. [CrossRef]
160. Takahashi, Y.; Iida, K.; Takahashi, K.; Yoshioka, S.; Fukuoka, H.; Takeno, R.; Imanaka, M.; Nishizawa, H.;
Takahashi, M.; Seo, Y.; et al. Growth hormone reverses nonalcoholic steatohepatitis in a patient with adult
growth hormone deficiency. Gastroenterology 2007, 132, 938–943. [CrossRef]
161. Nishizawa, H.; Iguchi, G.; Fukuoka, H.; Takahashi, M.; Suda, K.; Bando, H.; Matsumoto, R.; Yoshida, K.;
Odake, Y.; Ogawa, W.; et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a
p53-dependent manner. Sci. Rep. 2016, 6, 34605. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2019, 20, 2841 34 of 34
162. Attanasio, A.F.; Bates, P.C.; Ho, K.K.; Webb, S.M.; Ross, R.J.; Strasburger, C.J.; Bouillon, R.; Crowe, B.;
Selander, K.; Valle, D.; et al. Hypoptiuitary Control and Complications Study International Advisory Board.
Human growth hormone replacement in adult hypopituitary patients: long-term effects on body composition
and lipid status–3-year results from the Hypo CCS Database. J. Clin. Endocrinol. Metab. 2002, 87, 1600–1606.
163. Molitch, M.E.; Clemmons, D.R.; Malozowski, S.; Merriam, G.R.; Vance, M.L. Endocrine Society. Evaluation
and treatment of adult growth hormone deficiency: An Endocrine Society clinical practice guideline. J. Clin.
Endocrinol. Metab. 2011, 96, 1587–1609. [CrossRef]
164. Takano, S.; Kanzaki, S.; Sato, M.; Kubo, T.; Seino, Y. Effect of growth hormone on fatty liver in
panhypopituitarism. Arch. Dis. Child. 1997, 76, 537–538. [CrossRef] [PubMed]
165. Matsumoto, R.; Fukuoka, H.; Iguchi, G.; Nishizawa, H.; Bando, H.; Suda, K.; Takahashi, M.; Takahashi, Y.
Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth
hormone deficiency. Growth Horm. IGF Res. 2014, 24, 174–179. [CrossRef] [PubMed]
166. Sesmilo, G.; Biller, B.M.; Llevadot, J.; Hayden, D.; Hanson, G.; Rifai, N.; Klibanski, A. Effects of growth
hormone administration on inflammatory and other cardiovascular risk markers in men with growth
hormone deficiency. A randomized, controlled clinical trial. Ann. Intern Med. 2000, 33, 111–122. [CrossRef]
167. Fukuda, I.; Hizuka, N.; Yasumoto, K.; Morita, J.; Kurimoto, M.; Takano, K. Metabolic co-morbidities revealed
in patients with childhood-onset adult GH deficiency after cessation of GH replacement therapy for short
stature. Endocr. J. 2008, 55, 977–984. [CrossRef]
168. Zhang, H.; Liu, Y.; Wang, L.; Li, Z.; Zhang, H.; Wu, J.; Rahman, N.; Guo, Y.; Li, D.; Li, N.; et al. Differential
effects of estrogen/androgen on the prevention of nonalcoholic fatty liver disease in the male rat. J. Lipid Res.
2013, 54, 345–357. [CrossRef]
169. Grossmann, M.; Wierman, M.E.; Angus, P.; Handelsman, D.J. Reproductive Endocrinology of Nonalcoholic
Fatty Liver Disease. Endocr. Rev. 2019, 40, 417–446. [CrossRef]
170. Li, J.; Su, J.M.; Zeng, X.J. Is primary biliary cirrhosis another example of an immune-mediated complication
of klinefelter syndrome? J. Clin. Rheumatol. 2004, 10, 286–287. [CrossRef]
171. Tian, Y.; Wang, C.; Liu, J.X.; Wang, H.H. Primary Biliary Cirrhosis-Related Autoimmune Hemolytic Anemia:
Three Case Reports and Review of the Literature. Case Rep. Gastroenterol. 2009, 3, 240–247. [CrossRef]
[PubMed]
172. Machlab, S.; Miquel, M.; Voltà, T.; Escoda, M.R.; Vergara, M. Turner syndrome as a cause of liver cirrhosis.
Gastroenterol. Hepatol. 2018, 41, 308–309. [CrossRef] [PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
